Mechanistic Insights into the Pharmacological Significance of Silymarin

Karan Wadhwa 1, Rakesh Pahwa 2, Manish Kumar 3, Shobhit Kumar 4, Prabodh Chander Sharma 5, Govind Singh 3, Ravinder Verma 6, Vineet Mittal 1, Inderbir Singh 7, Deepak Kaushik 1,* and Philippe Jeandet 8,*

1 Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak 124001, Haryana, India
2 Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136119, Haryana, India
3 M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Ambala 133207, Haryana, India
4 Department of Pharmaceutical Technology, Meerut Institute of Engineering and Technology (MIET), Meerut 250005, Uttar Pradesh, India
5 Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, Delhi, India
6 Department of Pharmacy, G.D. Goenka University, Sohna Road, Gurugram 122103, Haryana, India
7 Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India
8 Research Unit-Induced Resistance and Plant Bioprotection, University of Reims, EA 4707-USC INRAe 1488, SFR Condorcet FR CNRS 3417, 51687 Reims, France
* Correspondence: deepkaushik1977@gmail.com (D.K.); philippe.jeandet@univ-reims.fr (P.J.)

Abstract: Medicinal plants are considered the reservoir of diverse therapeutic agents and have been traditionally employed worldwide to heal various ailments for several decades. Silymarin is a plant-derived mixture of polyphenolic flavonoids originating from the fruits and akenes of Silybum marianum and contains three flavonolignans, silybins (silybins), silychristin and silydianin, along with taxifolin. Silybins are the major constituents in silymarin with almost 70–80% abundance and are accountable for most of the observed therapeutic activity. Silymarin has also been acknowledged from the ancient period and is utilized in European and Asian systems of traditional medicine for treating various liver disorders. The contemporary literature reveals that silymarin is employed significantly as a neuroprotective, hepatoprotective, cardioprotective, antioxidant, anti-cancer, anti-diabetic, anti-viral, anti-hypertensive, immunomodulator, photoprotective and detoxification agent by targeting various cellular and molecular pathways, including MAPK, mTOR, β-catenin and Akt, different receptors and growth factors, as well as inhibiting numerous enzymes and the gene expression of several apoptotic proteins and inflammatory cytokines. Therefore, the current review aims to recapitulate and update the existing knowledge regarding the pharmacological potential of silymarin as evidenced by vast cellular, animal, and clinical studies, with a particular emphasis on its mechanisms of action.

Keywords: anti-inflammatory; antioxidant; pharmacological interventions; pro-apoptotic; silybin; silymarin

1. Introduction

Herbal medicaments have been commonly utilized as therapeutic moieties across the globe for therapy and management of a wide array of ailments. Despite the vast advancements in the current medicinal system, medicinal plants still play an imperative role in humans’ well-being [1]. From ancient times, numerous indigenous plants have been employed worldwide to treat various illnesses. Among the diversity of medicinal plants, Silybum marianum, one of the most primordial and systematically researched plants, has been widely employed from ancient times as a natural medication for various liver diseases and some digestive issues of the upper gastrointestinal tract [2]. Indeed, S. marianum, belonging to the Asteraceae/Compositae family, is commonly named ‘milk thistle’ because
of the presence of milky white veins on its leaves, which on breakage liberate a milky sap [3]. It is an inhabitant of the Mediterranean but has also grown for centuries all through North Africa, Europe and the Middle East region. In India, this plant is commonly found in Jammu and Kashmir at 1800–2400 m [4]. Silymarin, the standardized seed extract of milk thistle, has been extensively utilized as a broad-spectrum medicinal herb for a very long time [5,6]. From an ethnopharmacological point of view, silymarin has been employed for more than two centuries as a herbal therapy for protecting the liver from varied toxic matters, treating hepatic damage and for treatment of hepatitis as well cirrhosis [7,8]. Silymarin has also been used as an antidote for insect stings, snake bites, mushroom poisoning and alcohol [9–11].

Chemically, silymarin is a polyphenolic flavonoid extract consisting of about 70–80% silymarin flavonolignans along with 20–35% fatty acids and several other polyphenolic components [12]. Amongst all flavonolignans, silibinin (silybin), (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo [b][1,4] dioxin-6-yl]chroman-4-one (Figure 1), is the foremost active compound present in silymarin with almost 60–70% abundance and exists in the form of two diastereomers, silybin A and silybin B [13]. The pathways for silybin biosynthesis are somehow not clearly identified, but specific biomimetic syntheses assert that the coupling of taxifolin and coniferyl alcohol via peroxidase activity leads to silybin formation [14,15]. The other flavonolignans available in silymarin consist of isosilybin (5%), silychristin (20%) and silydianin (10%). As with silybin, isosilybin also naturally occurs in two diastereomeric forms, i.e., isosilybin A and isosilybin B (Figure 1). Some minor flavonolignans that are also present in silymarin include silimonin and isosilychristin [16]. Apart from flavonolignans, taxifolin is an essential flavonoid found in silymarin [17–19].

Evidence from preclinical and clinical research has revealed that silymarin and its flavonolignans significantly impart antioxidant, anti-inflammatory and pro-apoptotic properties, inducing numerous biological and pharmacological activities, for instance, hepatoprotection, neuroprotection, anti-diabetic properties, anti-cancer properties, cardioprotection, photoprotection, immunomodulation and many more. In the United States, there is no quality control and regulation of herbal compounds such as silymarin as they are not considered drugs and are not under the supervision of the US Food and Drug Administration [20]. Because of its excellent therapeutic efficacies, it is one of the most widely used dietary supplements and around 75 brands of silymarin are available on the market in different dosage forms (tablets, capsules, syrups, etc.) with enhanced bioavailability under trade names such as Livergol®, Silipide®, Carsil® tablets, Legalon® capsules and Alrin-B® syrup. Nano silymarin OIC, approved by the Vietnam Drug Administration, is the only patented nanof ormulation that is commercially available as a dietary supplement, in the form of capsules, for improving liver function [21–23].

Silymarin offers several benefits in contrast to other therapeutic agents because of its non-toxicity and excellent hydrophobic properties. It has low aqueous solubility which results in poor bioavailability. This issue can be resolved by employing a nanosystems-based approach. Nanoparticles are naturally or chemically synthesized particles that have a particle size range of 1–200 nm. Because of their small size range, they offer various advantages, such as an enhanced interaction area, enhanced aqueous solubility and intracellular permeability. In addition, they can reduce the multi-drug resistance of many anti-cancer agents, including silybin. These are distributed across the body depending upon various factors, such as their small size which aids in longer systematic circulation periods and their potential to take advantage of anti-cancer properties. They also show greater stability during storage. Nanoparticles and their use in drug delivery are a much more efficient approach for cancer treatment than traditional chemotherapy [24–26].
Elfaky et al. (2022) investigated the hepatoprotective potential of silymarin nanoparticles (NPs) with different particle size in Sprague Dawley adult male rats. They reported that large silver NPs are more effective in hepatoprotective action compared to small NPs [27]. Abdullah et al. (2022) designed a novel nanoformulation of silymarin-loaded chitosan NPs for improving anti-fibrotic potential against liver fibrosis. NPs were developed using the ionotropic gelation method. The authors reported that the developed formulation resulted in significant anti-fibrotic action against CCl₄-induced hepatic injury [28]. Patel et al. (2022) also developed silybin-loaded NPs for inhalation with caprolactone/pluronic F68 for the treatment of lung cancer. Pharmacokinetic investigations have revealed that the developed NPs enhanced silybin bioavailability, with a more than 4-times increase in AUC in contrast to i/v administration [29]. In another study, Iqbal et al. (2022) engineered Silybum marianum-mediated biosynthesized copper oxide NPs and investigated their various biological activities, such as anti-microbial properties, catalytic properties, anti-diabetic properties, antioxidant properties and ROS/RNS inhibition. They concluded that the developed NPs have significant in vitro biological and biomedical activities. They can be employed as broad spectrum agents for various biomedical applications [30]. Finally, Staroverov et al. (2021) fabricated silymarin–selenium NP conjugates with 30–50 ± 0.5 nm particle size. The developed conjugates enhanced cellular dehydrogenase activity and facilitated its penetration into intracellular spaces [31].

It has also been reported that co-administration of silymarin with some therapeutic agents may enhance its biological activity that is reduced by the liver, such as amitriptyline,
diazepam, celecoxib, fluvastatin, diclofenac, zileuton, ibuprofen, glipizide, losartan, irbesartan, piroxicam, tolbutamide, torsemide, tamoxifen and phenytoin [32]. Han et al. (2009) reported that the coadministration of different sources of silymarin with losartan significantly improved the systemic concentration of Losartan [33]. Similarly, Molto et al. (2012) examined the effect of co-administration of silymarin with darunavir and ritonavir combinations in HIV patients. They reported a decline in AUC and C\text{max} when co-administration of silymarin was used in combination with drugs compared to combinations of the drugs alone [34].

Considering the potential properties of silymarin, the present review has been designed to provide an insight into its numerous pharmacological activities with detailed information about its mechanisms of action.

2. Pharmacological Aspects of Silymarin

Silymarin possesses a tremendous array of biological and pharmacological potential by interacting directly or indirectly with several molecular targets, including transcription factors, inflammatory mediators, protein kinases, receptors and enzymes, as illustrated in Figure 2.

2.1. Hepatoprotective Activity

The liver is the vital organ for metabolism of xenobiotics, lipids and numerous environmental pollutants and helps eliminate many substances from the body [35]. Silymarin has a prolonged history of traditional use in Ayurvedic medicine as a hepatoprotective agent and is nowadays broadly employed in the treatment and management of numerous hepatic disorders such as alcoholic liver disease, hepatic cancers, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and drug toxicity, as mentioned in Table 1. Numerous studies have been conducted on the potent hepatoprotective actions of silymarin and its flavonolignans in the last decade. The various proposed mechanisms through which silymarin exerts its hepatoprotective activity are represented in Figure 3. Initially, gamma-glutamyl transferase (γGT), glutamic-oxalacetic transaminase (SGOT), glutamic pyruvic transaminase (SGPT) and alkaline phosphate (ALP) are essential and characteristic enzymes of the liver, and their elevated levels indicate hepatotoxicity. Silymarin was found to decrease the levels of these hepatic enzymes and prevent cellular escape and loss of functional integrity of hepatocyte membranes. Additionally, silymarin and its flavonolignans have a significant role in the reduction of cholesterol (CH), triglyceride (TG) and low-density lipoprotein (LDL) levels along with elevation of the content of high-density lipoproteins (HDL) [36–40].

Figure 2. Various molecular targets for silymarin.
Table 1. Experimental hepatoprotective activity of silymarin.

| Study Model                                | Dose/Concentration Used          | Possible Target Site/Mechanism of Action                                                                 | Reference |
|--------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------|-----------|
| CCl₄-induced hepatotoxicity                | 200 mg/kg p.o.                   | • Decrease in the levels of ALP, SGPT, and SGOT  
• Reverses the altered expressions of α-SMA                                                          | [41]      |
| CCl₄-induced hepatotoxicity                | 200 mg/kg p.o.                   | • Reduction in the levels of γ-GT, SGPT, SGOT, ALP, TGF-β1, IL-6 and hydroxyproline  
• Down-regulation of α-SMA expressions                                                              | [42]      |
| Valproic acid-induced hepatotoxicity       | 25 and 50 mg/kg                  | • Reduction in the levels of LDH, SGPT, SGOT, ALP  
• Increase in GSH levels                                                                              | [43]      |
| Thioacetamide-induced hepatotoxicity       | 100 mg/kg p.o.                   | • Down-regulation of TGF-β, AP-1, α-SMA, MMP-2 and 13, COL-α1, TIMP-1 and 2 and KLF6 expressions     | [44]      |
| Fructose-induced NAFLD                    | 400 mg/kg/day p.o.               | • Reduction in MDA, SGPT, SGOT, hepatic TG, CH and LDL                                                | [39]      |
| Diclofenac-induced hepatotoxicity          | 200 mg/kg p.o.                   | • Decrease in the levels of MDA, ALP, SGPT, SGOT and TNF-α  
• Elevation in the level of SOD, GSH and CAT                                                           | [45]      |
| CCl₄-induced hepatotoxicity and HSC cells  | 20 and 100 mg/kg p.o.             | • Down-regulation of MCP-1, TGF-β and collagen 1 expression                                           | [46]      |
| CCl₄-induced hepatotoxicity                | 100 mg/kg i.p.                   | • Reduction in the levels of MDA, GSH, LDL, TG, SGPT, SGOT and ALP                                    | [47]      |
| CCl₄-induced hepatotoxicity                | 100 mg/kg i.p. 5 times a week for 4 weeks | • Decrease in TG, CH, VLDDL-C, ALP, SGPT and SGOT levels  
• Increase in the levels of SOD, GSH and GST  
• Reduction in levels of TBARS, TGF-β1, TNF-α, IL-6, hydroxyproline and resistin | [40]      |
| Acetaminophen-induced hepatotoxicity       | 200 mg/kg p.o.                   | • Decrease in the levels of SGPT and SGOT  
• Elevation in γ-GT and MPO levels                                                                      | [48]      |
| NASH rats                                  | 200 mg/kg p.o.                   | • Reduction in the levels of serum insulin, HOMA-IR, SGOT, LDL, TG and TNF-α                        | [49]      |
| HFD-induced NAFLD                          | 5-10 mL/kg p.o. for 8 weeks      | • Elevation in the levels of SOD, CAT and PPARα  
• Reduction in levels of MDA, TNF-α, IL-6, SREBP-1c, FAS and LXRα                                    | [50]      |
| MCD diet-induced NASH                      | 105 mg/kg/day p.o. for 8 weeks   | • Up-regulation of the Nrf2 pathway  
• Decrease in the levels of TNF-α, IL-6, IL-1β, IL-12β, p-IKKα/β, p-IκBα and p-p65  
• Down-regulation of the NF-κB pathway                                                                 | [51]      |
| Study Model                              | Dose/Concentration Used | Possible Target Site/Mechanism of Action                                                                                                                                                                                                 | References |
|------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| MCD diet-induced NASH                    | —                       | • Reduction in the levels of SGPT and SGOT  
• Increase in TNF-α, TGF-β and MDA levels  
• Modulates caspase-3 activation                                                                                                                                  | [52]       |
| Restraint of stress-induced acute liver injury | 100 mg/kg              | • Decrease in MDA and 4-HNE levels  
• Inhibition of JNK activation  
• Down-regulation of Bid, Bax and caspase-3 and 8, as well as PARP cleavage                                                                                                                   | [53]       |
| HepG2 cells and HFD-induced liver inflammation | 50 or 100 mg/kg per day | • Inhibition in colocalization of NLRP and α-tubulin  
• Down-regulation of cleaved caspase-1 and thioredoxin-interacting protein  
• Prevents release of IL-1β                                                                                                                                        | [54]       |
| —                                        | 600 mg/kg per day p.o. for 10 days | • Reduction in the levels of c-Kit, c-Myc, Oct3/4 and SSEA-1 markers  
• Decrease in the levels of MDA, SGPT, SGOT and MPO                                                                                                                  | [55]       |
| HepG2 cells (Benzo[a]pyrene-induced hepatotoxicity) | 0–40 µM                | • Up-regulation of Nrf2 and PXR  
• Prevents DNA damage                                                                                                                                                                                                               | [56]       |
| CCl₄-induced hepatotoxicity              | 50 and 200 mg/kg        | • Reduction in TGF-β and α-SMA expression  
• Decrease in the levels of hyaluronic acid  
• Suppresses Kupffer cells activation                                                                                                                                 | [57]       |
| Zidovudine and isoniazid-induced liver toxicity | 100 mg/kg              | • Elevation in the levels of SOD, CAT  
• Reduction in the levels of MDA, SGPT, SGOT and ALP                                                                                                                     | [58]       |
Oxidative stress has a critical position during the progression of NAFLD and hepatic steatosis [59], and the use of exogenous natural antioxidants such as silymarin can trigger various antioxidant enzymes and stimulate non-enzymatic nuclear factor erythroid 2-related factor 2 (Nrf2) pathways, which consequently diminishes oxidative stress [14,51,60]. Recently, Mengesha et al. (2021) evaluated the hepatoprotective effect of silymarin using a fructose-induced NAFLD rat model and concluded that silymarin significantly improves lipid profile and liver function along with amelioration of oxidative stress status [39]. Zhu et al. (2018) reported that *S. marianum* oil impedes oxidative stress in high-fat diet (HFD) rats by elevating the levels of endogenous antioxidant enzymes. Moreover, it was also observed that oral administration of this oil improves hepatic fatty acid synthesis and fatty acid oxidation by reducing the mRNA levels of the fatty acid synthase (FAS), the liver X receptor α and the sterol regulatory element-binding protein 1c (SREBP-1c) [50].

Along with oxidative stress, inflammation is considered to be another imperative mediator of NAFLD and NASH. Preclinical and clinical substantiations revealed that silymarin demonstrates anti-inflammatory actions via repressing the release of cytokines [51–54,57,61]. Ou et al. (2018) reported that silymarin supplementation to methionine–choline deficient (MCD) diet-induced NASH mice significantly diminishes levels of the pro-inflammatory cytokines tumor necrosis factor (TNF)-α, Interleukin (IL)-6, IL-1β and IL-12β [51]. Most of silymarin’s anti-inflammatory hepatoprotective effects have focused on cytokine release; however, Zhang et al. (2018) observed that silybin significantly impedes NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in NAFLD by elevating NAD⁺ levels, which as a result preserves the effect of the NAD⁺-dependent α-tubulin deacetylase sirtuin (SIRT)2 and restrains the activation of the acetylated α-tubulin promoted NLRP3 inflammasome, thus indicating the potential of silybin for targeting the NAD⁺/SIRT2 pathway [54]. Apart from its anti-inflammatory action, several studies claimed that the immunomodulatory effect of silymarin and its bio-constituents could also play a remarkable role in hepatoprotection [14,62]. The anti-apoptotic and pro-apoptotic behavior of silymarin also considerably facilitates liver protection. Indeed, elevated oxidative stress and excessive discharge of pro-inflammatory cytokines can persuade apoptosis by stimulating the c-Jun NH2-terminal kinase (JNK) signaling pathway [63]. Kim et al. (2016) also showed that silymarin administration to stressed mice attenuates JNK activation and its associated apoptotic signaling by down-regulating the expression of Bid, Bax, caspase-3 and caspase-8 as well as poly adenosine diphosphate-ribose polymerase (PARP) cleavage [53].

Various animal and cell-based studies have revealed that silymarin and its bioactive constituents significantly impair the progression of initial liver fibrosis and its associated fibrogenetic mechanisms and induce a hepatoprotective behavior. In chronic liver injury, such as hepatitis C virus (HCV) infection, fibrosis and inflammation produce fibrous scarring through the activation of myofibroblasts in the liver, which consequently exudes extracellular matrix proteins. However, the augmentation of hepatic stellate cells (HSCs) and Kupffer cells is considered as the decisive episode in the production of hepatic fibrosis [14,64]. Experimental investigations have shown that silymarin impairs the proliferation of HSCs and prevents their translation into myofibroblasts, while also down-regulating gene expression of the extracellular matrix components required during fibrosis [57,65]. In a study by Clichici et al. (2015), silymarin was reported to decrease collagen and procollagen III by 30% after biliary obstruction in rats [57]. Activated HSCs also display an increase in expression of the monocyte chemoattractant protein-1 (MCP-1), which is an essential chemokine responsible for controlling monocyte/macrophage movement and permeation [66,67]. Mahli et al. (2015) have affirmed that silymarin treatment down-regulates MCP-1 and collagen 1 expression upon CCl₄-induced hepatotoxicity in rats [46]. Silymarin also down-regulates the expression of α-smooth muscle actin (α-SMA), which directly triggers HSCs to activate myofibroblast-like cells [42,44,57]. Furthermore, the tissue inhibitor of metalloproteinases 1 (TIMP-1) also controls the alteration of the extracellular matrix in hepatic fibrosis via MMPs [68]. Silymarin significantly improves the level of MMP-2 and prevents fibrosis [44,61,69]. Notably, Chen et al. (2012) discovered that silymarin at a dose
of 100 mg/kg significantly down-regulates transforming growth factor-beta 1 (TGF-β), activator protein-1 (AP-1), α-SMA, MMP-2, MMP-13, collagen-α1 (COL-α1), TIMP-1, TIMP-2 and krueppel-like factor 6 (KLF6) expressions in a thioacetamide-induced hepatotoxicity rat model [44]. Furthermore, hepatocyte apoptosis prompts HSC activation and hepatic fibrosis; noteworthy treatment with silybin also reduces these changes [51].

Kupffer cells, on the contrary, induce fibrosis via the production of Kupffer cell-derived TGF-β1, which consequently activates myofibroblasts. Moreover, Kupffer cells also regulate the synthesis of MMP and TIMPs. Silymarin also significantly obstructs activation and function of Kupffer cells [57,70]. Likewise, several other pro-inflammatory cytokines, such as leptin and resistin, act as fibrogenic markers and stimulate fibrogenesis by activating portal fibroblasts, especially HSCs. Silymarin also down-regulates the expression of these fibrogenic markers and prevents hepatic fibrosis [40,42,51,52]. The anti-inflammatory ability of silymarin to impair nuclear factor-kappa B (NF-kB) also remarkably retards HSC proliferation [40].

Besides the aforementioned mechanisms, silymarin and its flavonolignans also induce hepatoprotective effects by anticipating liver regeneration and blocking toxic substances. Hepatocyte regeneration significantly recovers the liver from acute and chronic damage. It has been established that silymarin administration triggers hepatic regeneration by augmenting ribosomal RNA and RNA polymerase I synthesis, which consequently stimulates protein synthesis and repairs damaged liver cells [71,72].
2.2. Anti-Diabetic Activity

Increased diabetes mellitus (DM) and its associated complications are considered a global burden. DM is a progressive metabolic disorder characterized by chronic persistent hyperglycemia, insulin resistance and impaired insulin synthesis with elevated hepatic glucose outputs [73,74]. Silymarin and its constituents have been described for their potential hypoglycemic effects, and accumulating experimental and clinical evidence suggested that silymarin extensively trims down the blood glucose level and boosts insulin secretion (Table 2 and Figure 4) [75–84].

Results from streptozotocin (STZ)-induced diabetic rat models demonstrated that silymarin, when administered orally at a dose of 80 mg/kg for 21 days, remarkably reduces HbA1c levels and fasting blood sugar (FBS) levels [77]. Silymarin also imparts potential anti-diabetic activity by impeding gluconeogenesis and glucose-6-phosphatase (G6Pase) activity [85].

![Figure 4. Various anti-diabetic mechanisms of silymarin.](image_url)
Table 2. Experimental anti-diabetic activity of silymarin.

| Study Model                                      | Dose/Concentration Used                      | Possible Target Site/Mechanism of Action                                                                 | Reference |
|-------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Obesity-induced insulin resistance model and HepG 2 cells | 30 mg/kg/day p.o. for one month              | • Elevation in SIRT1 expression<br>• Decrease in Akt and FOXO1 phosphorylation<br>• Increase in enzymatic activity of SIRT1 | [86]      |
| HFD model                                       | 30 mg/kg/day p.o. for one month              | • Decrease in insulin resistance<br>• Reduction in hepatic NADPH oxidase expression and NF-κB activity<br>• Decrease in GSH, CAT and SOD activity<br>• Reduction in IL-6, iNOS, NO and TNF-α levels | [75]      |
| HFD-induced insulin resistance                  | 30 and 60 mg/kg p.o.                         | • Reduction in TNF-α, IL-1β and IL-6 levels<br>• Decrease in the levels of SGOT, SGPT, CH, TG and LDL<br>• Decrease in insulin resistance | [87]      |
| HFD-induced insulin resistance model and HEK293T cells | 40 µg/mL 50 µM                              | • Reduction in FBS levels<br>• Inhibition of NF-κB signaling<br>• Activation of Farnesyl X receptor | [79]      |
| Pancreatectomy model                             | 200 mg/kg p.o.                              | • Increase in serum insulin levels<br>• Improvement in β cell proliferation<br>• Elevation in Pdx1 and insulin gene expression | [88]      |
| STZ-induced diabetes and INS1 cells             | 50 µg/mL 2.5–100 µM                          | • Decrease in FBS and increase in insulin secretion<br>• Elevation in Bax and cleaved-caspase-3 protein levels<br>• Reduction in Bcl-2 and pro-caspase-3 gene expression | [89]      |
| STZ- and HFD-induced diabetes                    | 100 and 300 mg/kg p.o.                       | • Decrease in hepatic glucose production<br>• Increase in expression of the GLP-1 receptor in the duodenum | [90]      |
| STZ-induced diabetes                             | 60 and 120 mg/kg/day for 2 months            | • Down-regulation of urotensin II gene expression<br>• Reduction in FBS, CK-MB, LDH, MDA, CH, LDL and NO levels | [76]      |
| STZ-induced diabetes                             | 80 mg/kg p.o. for 21 days                   | • Reduction in HbA1C levels<br>• Reduction in the levels of MDA, SGOT, SGPT, LDH and CK-MB in the heart<br>• Decrease in the levels of CH, TG and LDL<br>• An increase in Bcl-2 and decrease in Bax levels prevents apoptosis | [77]      |
Chronic hyperglycemia blights the mitochondrial respiratory chain and produces oxidative damage, resulting in the growth and development of DM and its associated complications. Treatment with silymarin significantly prevents oxidative damage by impeding lipid peroxidation, protein oxidation and reactive oxygen species (ROS) generation [75, 91, 92]. Qin et al. (2017) observed that silychristin A, one of the bioactive compounds of silymarin extracts, significantly protects ROS-induced apoptosis in INS 1 cells by elevating Bax and cleaved-caspase-3 protein levels and down-regulating Bcl-2 and pro-caspase-3 gene expressions [89]. Along with oxidative stress, inflammation is a key factor in diabetes progression and complications. Inflammatory cytokines have a decisive role in managing glucose homeostasis and insulin resistance. Any abnormal change in pro-inflammatory cytokines (IL-6 and TNF-α) could diminish insulin sensitivity and contribute to insulin resistance. In contrast, infiltrations of these cells can cause pancreatic β-cell failure [87]. Several studies have indicated that treatment with silymarin alleviates the inflammatory response by impeding the levels of NF-kB target genes [87, 93]. It has been observed that silymarin also suppresses Interferon-γ (IFN-γ), TNF-α and IL-1β-induced nitric oxide (NO) generation, while also suppressing inducible nitric oxide synthase (iNOS) expression in pancreatic β-cells through modulating NF-kB activity and the extracellular signal-regulated kinase1/2 (ERK1/2) signaling pathway, which subsequently prevents pancreatic β-cell degradation [93].

An experiment by Xu et al. (2018) postulated that silybin decreases hepatic glucose production in STZ/high-fat diet (HFD) diabetics. Furthermore, it was observed that silybin also modulates the expression of the glucagon-like peptide (GLP)-1 receptor in the duodenum and activates neurons around the solitary tract, demonstrating the anti-diabetic potential of silymarin by eliciting the gut–brain–liver axis [90]. The Pdx1 transcription factor is believed to be directly involved in pancreatic growth and insulin gene expression, and the results from the study performed by Soto et al. (2014) revealed that silymarin elevates Pdx1 and insulin gene expression in pancreatectomized rats along with improvements in β-cell proliferation. Furthermore, it was also reported that silymarin administration up-regulates NKx6.1 gene expression, responsible for the differentiation, neogenesis and maintenance of β-pancreatic cells [94]. A current study by Feng et al. (2021) has demonstrated that silymarin administration elevates SIRT1 expression in hepatocytes [86]. Furthermore, this study, also conducted on HepG2 cells in vitro, confirmed that silymarin binds to the SIRT1 enzyme and enhances its activity, thereby indicating the potent action of silymarin on insulin resistance and gluconeogenesis [86]. Silymarin and silybin also alleviate diabetes and other related metabolic syndromes by up-regulating Farnesyl X receptor signaling when studied in vitro using HEK293T cells [79].

Furthermore, it was also observed that silybin activates the insulin receptor substrate 1/phosphoinositide 3-kinase/protein kinase B (IRS-1/Pi3K/Akt) pathway, which consequently elevates insulin-mediated glucose uptake and glucose transporter-4 (GLUT4) translocation [95]. Recent studies affirmed that estrogen receptors play an essential role in glucose metabolism and preserve islet β-cell functionality and viability. Silymarin treatment significantly up-regulates the expression of both estrogen receptors α and β and protects β-cells from the progression of DM [96–98].

Moreover, silymarin also attenuates DM-associated complications. It has been observed that silymarin also plays an imperative role in treating diabetic-induced neuropathy, nephropathy, cardiomyopathy, hepatopathy and delayed healing [99]. Recently, Rahimi et al. (2018) reported that silymarin down-regulates urotensin II gene expression, which is responsible for diabetic-associated cardiomyopathy by causing insulin resistance, inflammation and endothelial damage [76]. Furthermore, silymarin protects cardiomyocytes against DM-induced apoptosis by elevating Bcl-2 levels and down-regulating Bax expression [77, 100]. Results from Meng et al. (2019) revealed that silymarin treatment also impedes the TGF-β1/Smad signaling pathway and improves cardiac fibrosis and collagen deposition in diabetic cardiomyopathy [101].
Silymarin also displays protective effects against diabetes-induced nephropathy. It significantly attenuates oxidative stress in the renal tissues by modulating the activity of various antioxidant enzymes [102,103]. Guzel et al. (2020) reported that silymarin at a 200 mg/kg dose significantly reduces caspase activity and the levels of malondialdehyde (MDA), NO and serum creatinine, while also possessing effective renal function that protects against vancomycin-induced nephropathy in rats [104]. Chen et al. (2021) demonstrated that chronic administration of silymarin down-regulates IL-6 and intercellular adhesion molecule-1 (ICAM-1) expressions and alleviates TGF-β/Smad and JAK2/STAT3/SOCS1 pathways using an STZ-induced diabetic nephropathy model of rats with improvements in podoxin and nephrin levels [105]. Nevertheless, clinical studies also revealed that silymarin suppresses urinary TNF-α and MDA levels, indicating protective effects against diabetes-induced nephropathy [106]. Zhang et al. (2014) reported that oral administration of silybin to STZ- and HFD-induced diabetic rats for 22 days down-regulates the expression of retinal ICAM-1, contributing to the prevention of diabetic retinopathy [107].

2.3. Anti-Cancer Activity

Cancer is a group of diseases characterized by proliferation and differentiation in the growth of abnormal cells, invading normal tissues or organs and eventually spreading to all parts of the body. Cancer is a significant public health concern, and about 19.9 million new cancer cases were diagnosed in 2020 globally and are expected to increase to 28.4 million cases in 2040 [108,109]. Plants have been used as medicines by humanity for generations, and their considerably lower toxicity, ease of availability and high specificity towards targets, compared to synthetic chemotherapeutic agents, have stimulated much interest among researchers hoping to develop plant-based anticancer drugs. Moreover, recent advancements in isolation and identification of phytochemicals have also attracted heightened attention in relation to the application of herbal medicines as a prospective target for cancer management [110,111].

Excessive investigational studies revealed that silymarin possesses anti-cancer activity against almost all types of cancers, including colorectal cancer, bladder cancer, breast cancer, gastric cancer, prostate cancer, skin cancer, lung cancer, hepatocellular carcinoma, laryngeal carcinoma, glioblastoma and leukemia, as mentioned in Tables 3 and 4 [7,112,113]. Silymarin and its bioactive constituents can curb the rise of different tumor cells, which is achieved by cell cycle arrest at the G1/S-phase, activation of cyclin-dependent kinase (CDK) inhibitors, reduction in anti-apoptotic gene product formation, obstruction of cell survival kinases and down-regulation of inflammatory transcription factors. Moreover, silymarin can also alter the expression of gene products associated with the proliferation of different tumor cells, their invasion, metastasis and angiogenesis [7,113]. The principal mechanisms of silymarin as an anti-cancer agent are mentioned in Figure 5. Nonetheless, silymarin and its bioactive constituents are also used in the prophylaxis of numerous anti-cancer therapy-induced side effects, such as the capecitabine-induced hand-foot syndrome [114], cisplatin-induced nephrotoxicity [115,116] and radiation-induced mucositis and dermatitis [117–119].
### Table 3. Experimental anti-cancer activity of silymarin.

| Type of Cancer | Study Model | Dose/Concentration Used | Possible Target Site/Mechanism of Action | Reference |
|----------------|-------------|-------------------------|----------------------------------------|-----------|
| Bladder cancer | T24 and UM-UC-3 cells | 10 µM | • Down-regulation of the actin cytoskeleton and PI3K/Akt pathway | [120] |
| MDA-MB-231 and MCF-7 breast cancer cells in vivo xenograft tumor model | 0-200 25 µg/mL and 50 mg/kg | • Reduction in the levels of Bcl-2, p-38 and p-ERK1/2 • Elevation in Bax, cleaved poly-ADP ribose polymerase, cleaved caspase-9, and JNK level | [121] |
| MCF-7 cells | 10-100 µM | • Inhibition of BCRP mRNA expression and cell viability | [122] |
| 4T1 tumor-bearing BA1B/c mice and myeloid-derived suppressor cells | 150 mg/kg | • Reduction in TNF-α, IL1β and CCR2 levels • Improved T cell count | [123] |
| MCH-7 and MDA-MB-231 cells | 30-90 µM 150-250 µM | • Reduction in MMP-2 and 9 protein expression • Elevation in E-cadherin expression and reduction in N-cadherin expression • Inhibition of NLRP3 inflammasome activation | [124] |
| MDA-MB-231 cells | 0-400 µM | • Reduction in the expression of Cdc42 and D4-GDI mRNA | [125] |
| MDA-MB-231 cells | 0-350 µM | • Inhibition of MMP-2 via inhibition of STAT3 | [126] |
| MCH-7 cells | — | • Reduction in AP-1 dependent MMP-9 gene expression | [127] |
| MCF-7 cells | — | • Down-regulation of MMP-9 and VEGF expression | [128] |
| MDA-MB-231 and T-47D | — | • Reduction in cytosolic free β-catenin level • Down-regulation of LPR6 and Axin2 expression | [129] |
| Azoxythenmethane-induced colon carcinogenesis model | 300 mg/kg p.o. for 7 days | • Reduction in the number of preneoplastic lesions • Down-regulation of Bcl-2 protein level and IL1β, TNF-α and MMP-7 gene expression | [130] |
| SW480 and SW620 cells | 300 µM | • Elevation in death receptor 4/5 mRNA expression • Activation of caspase-9 • Increase in expression of TRAIL | [131] |
| HCT116 and SW480 cells | 0-200 µg/mL | • Downregulation of CD1 levels | [132] |
| HCT116, SW480, LoVo and HT-29 cells | — | • Inhibition of p38, ERK1/2 and GSK3β protein expression | [133] |
| Xenograft tumor model | — | • Inhibition of the PP2Ac/AKT Ser473/mTOR pathway • Inhibition of cancer stem-like cell development | [134] |
Table 3. Cont.

| Type of Cancer                | Study Model                     | Dose/Concentration Used | Possible Target Site/Mechanism of Action                                                                 | Reference |
|------------------------------|---------------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------|-----------|
| Gastric cancer               | ASG human gastric cancer cells  | 20–120 µg/mL and 100 mg/kg | • Reduction in the levels of Bcl-2 and p-ERK1/2<br>• Elevation in Bax, cleaved poly-ADP ribose polymerase, cleaved caspase-9, p-P38 and JNK level | [135]     |
|                              | In vivo xenograft tumor model   |                         |                                                                                                           |           |
|                              | BGC-823 cells                   | 0–200 µM                | • Elevation in the levels of Bax<br>• Activation of caspase-3                                           | [136]     |
|                              | MGC-803 cells                   | 0–200 µM                | • Increase in caspase-3 and 9 expression<br>• Inhibition of p-STAT3, CDK1 and Cyclin B1 protein expression<br>• Reduction in Mcl-1, Bcl-xL and survivin levels | [137]     |
| Hepatocellular carcinoma     | Hep G2 cells                    | 0–200 µM                | • Increase in ceramide secretion<br>• Elevation in miRNA levels                                         | [138]     |
|                              | HCC cells                       | —                       | • Inhibition of EGFR-dependent Akt signaling                                                            | [139]     |
|                              | Hep G2 cell model and tumor xenograft model | 12.1–482.4 µg/mL       | • Decrease in the levels of CXC receptor-4 protein<br>• Down-regulation of the Slit-2/Robo-1 pathway        | [140]     |
|                              | HCC cell model and tumor xenograft model | 50–200 µM              | • Elevation in the apoptotic index and caspase-3 activity<br>• Down-regulation of Bcl-2, survivin and cyclin D1 level<br>• Reduction in Notch1 intracellular domain (NICD), RBP-Jk and Hes1 protein expression | [141]     |
|                              | N-nitrosodiethyl-amine-induced liver cancer | 1000 ppm              | • Inhibition of the recruitment of mast cells<br>• Reduction in MMP-2 and 9 expression                    | [142]     |
| Laryngeal carcinoma          | Hep 2 cells                     | 60–300 µM               | • Down-regulation of survivin expression                                                               | [143]     |
| Leukemia                     | K562 cells                      | 0–100 µg/mL             | • Inhibition of telomerase activity                                                                  | [144]     |
| Lung cancer                  | LA795, NCI-H299 cells and tumor xenograft models | 100 mg/kg            | • Inhibition of TMEM16A<br>• Reduction in vimentin, N-cadherin and β-catenin levels<br>• Down-regulation of CD1 expression | [145]     |
| Oral cancer                  | HSC-4, YD15 and Ca9.22 cells tumor xenograft models | 40–80 µg/mL, 200 mg/kg/day p.o. for 5 weeks | • Elevation in the expression of death receptor 5 and cleaved caspase-8 levels | [146]     |
|                              | MC3 and HN22 cells              | —                       | • Elevation in Bim expression<br>• Reduction in ERK1/2 levels                                           | [147]     |
|                              | SCC-25 cells                    | 50 and 100 µM           | • Reduction in Bcl-2 gene expression<br>• Over-expression of Bax, caspase-3 and caspase-9 genes       | [148]     |
## Table 3. Cont.

| Type of Cancer       | Study Model                                      | Dose/Concentration Used | Possible Target Site/Mechanism of Action                                                                 | Reference |
|----------------------|--------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Ovarian cancer       | A2780s and PA-1 cells                            | 50 and 100 µg/mL        | • Amplification of p53, p21, p27 and Bax protein expression  
• Decrease in Bcl-2 and CDK2 protein expression  
• Activation of caspase-9 and 3 | [149]     |
| Prostate cancer      | PC-3 and DU-145 cells                            | —                       | • Reduction in cytosolic free β-catenin levels  
• Down-regulation of LPR6 and Axin2 expression | [129]     |
|                      | DU-145 cells                                     | 15.6 to 1000 µM         | • Activation of SLIT2 protein  
• Down-regulation of CXC receptor 4 expression | [150]     |
| Skin cancer          | DMBA–TPA-induced skin papilloma and A431 cells   | 12.5–50 µM              | • Reduction in MAPK/ERK1/2 levels and up-regulation of JNK1/2 and p38 expression | [151]     |
|                      | A375 and Hs294t cells                            | 0–40 µg/mL              | • Reduction in β-catenin, MMP-2 and MMP-9 levels  
• Elevation in CK1α and GSK-3β levels | [152]     |
|                      | DMBA-TPA 2-stage skin carcinogenesis             | 9 mg topically          | • Down regulation of NO, TNF-α, IL-6, IL-1β, COX-2, iNOS and NF-κB | [153]     |
|                      | A375 and Hs294t cells tumor xenograft models     | 0–60 µg/mL and 500 mg/kg| • Up-regulation of Bax protein expression  
• Reduction in VEGF, CD31, Bcl-2 and Bcl-xl protein expression  
• Reduction in MMP-2, PCNA and CDK levels | [154]     |
|                      | MCF-7 and NCIH-23 cell lines                     | 12.5–200 µg/mL          | • Up-regulation of caspase-3, p53 and APAF gene expression | [155]     |
|                      | N-Butyl-N-(4-hydroxybutyl) nitrosamine-induced carcinogenesis | 1000 ppm                  | • Down-regulation of cyclin D1 expression causing G1 cell arrest | [156]     |
|                      | U266 MM cell                                     | 50–200 µM               | • Reduction in p-Akt, PI3K and p-mTOR protein expression | [157]     |
Table 4. Cellular pathways modulated by silymarin and its flavonolignans to induce anti-cancer activity.

| Type of Cancer                        | Cellular Pathway Modulated                                                                 | References |
|--------------------------------------|-------------------------------------------------------------------------------------------|------------|
| Bladder cancer                       | ↓ PI3K-PKB/Akt signaling pathway                                                          | [120]      |
| Cervical/ovarian cancer              | ↓ MAPK/ERK1/2 and MAPK/p38 signaling pathway:                                            | [158]      |
|                                      | ↓ Bcl-2-mediated anti-apoptosis                                                          |            |
| Prostate cancer                      | ↓ CDK, MAPK/ERK1/2, and Wnt/β-catenin signaling pathway                                   | [129,159,160] |
| Skin cancer                          | ↑ p53-mediated apoptosis and MAPK/p38 signaling pathway                                   | [151,161–163] |
|                                      | ↓ MAPK/ERK1/2, MAPK/JNK1 and Wnt/β-catenin signaling pathway                             |            |
| Lung cancer                          | ↑ Multiple MAPK signaling pathways                                                      | [145,164] |
|                                      | ↓ CDK signaling pathway                                                                  |            |
| Liver cancer (Hepatocellular carcinoma) | ↓ Bcl2-mediated anti-apoptosis                                                          | [140,141,165] |
|                                      | ↑ p53, Bax and APAF-1-mediated apoptosis                                                 |            |
|                                      | ↓ Slit-2/Robo-1 pathway and Notch pathway                                                |            |
| Breast cancer                        | ↓ MEK/ERK and Wnt/β-catenin signaling pathway                                            | [121,128,129] |
|                                      | ↓ Bcl-2-mediated anti-apoptosis                                                          |            |
| Oral cancer                          | ↑ Bim-mediated apoptosis                                                                 | [147]      |
|                                      | ↓ MAPK/ERK1/2 signaling pathway                                                          |            |
| Colorectal cancer                    | ↓ PP2A/AKT/mTOR, MAPK/ERK1/2 and MAPK/p38 signaling pathway                              | [130,133,134] |
|                                      | ↓ Bcl-2-mediated anti-apoptosis                                                          |            |
|                                      | ↑ Bax-mediated apoptosis                                                                 |            |
| Gastric cancer                       | ↓ MAPK/ERK signaling pathway                                                             | [128,135] |
|                                      | ↑ MAPK/p38 signaling pathway                                                             |            |
| Peripheral blood cancer              | ↓ PI3K-PKB/Akt signaling pathway                                                         | [166]      |
|                                      | ↑ Caspase-3-mediated apoptosis                                                           |            |

Figure 5. Anti-cancer mechanisms of silymarin.
Numerous observations have reported that silymarin and its bioactive constituents attenuate cellular growth and proliferation by modulating mitogen-activated protein kinase (MAPK) signaling and inducing apoptosis in vitro [133,135,147,151,158,164]. MAPK is a key signaling pathway responsible for transferring extracellular stimuli to the nucleus. MAPK is further alienated into three subtypes: (i) ERK1/2, which imperatively regulates tumorigenesis, including cellular proliferation, division and viability; (ii) JNK; and (iii) p38, which significantly controls inflammation by modulating pro-inflammatory cytokine production and cell death [167]. Singh et al. (2002) were the first to report that silybin impedes cell proliferation and stimulates apoptosis in A431 cells by inhibiting MAPK/ERK1/2 activation and up-regulating stress-activated protein kinase/JNK1/2 (SAPK/JNK1/2) and p38 MAPK [151].

It was found from in vitro studies that silymarin considerably encourages apoptosis in both A2780s and PA-1 cells by elevating Bax and diminishing Bcl-2 protein expression, along with escalating caspase-9 and caspase-3 [149]. Similarly, Vaid et al. (2015) confirmed that silymarin encourages apoptosis of human melanoma cells via the down-regulation of anti-apoptotic proteins, mainly Bcl-2 and Bcl-xl, and the up-regulation of pro-apoptotic proteins, i.e., Bax along with activation of caspases [154]. Interestingly, Yang et al. (2013) demonstrated that silybin also down-regulates survivin expression, an essential part of the inhibitors of the apoptotic protein family, which subsequently induces apoptosis of Hep-2 cells [143].

A study by Won et al. (2018) endorsed that silymarin activates death receptor 5 to persuade apoptotic cell death in HSC-4, YD15 and Ca9.22 oral cancer cell lines [146]. Interestingly, it was also explored that silybin elevates death receptor 4/5 mRNAs and TNF-related apoptosis-inducing ligand (TRAIL) mRNA expression along with activation of caspase-9, thus indicating a dual mechanism of silymarin inducing potential anti-cancer activity through the augmentation of both the extrinsic and intrinsic apoptotic pathways [131,168]. In addition to inducing an apoptotic effect, silymarin also increases the levels of ceramides and modulates the secretion of micro RNA (miRNA) by down-regulating miR-92-3p and up-regulating miR223-3p and miR16-5p, which usually act as oncogenes and tumor suppressors in carcinogenesis [138]. Most importantly, Zhang et al. (2015) concluded that silybin prevents glioma cell proliferation and induces apoptosis via impeding PI3K and Forkhead box M1 9 (FoxM1) expression, which further triggers the mitochondrial apoptotic pathway [169].

Furthermore, preventing cellular proliferation by disrupting typical cell cycle sequences and cellular divisions at various cell cycle stages is an important mechanistic approach to inducing anti-tumor activity. Cyclins, CDKs and cyclin-dependent kinase inhibitors (CDKIs) are critical cell cycle regulators which are overexpressed during cancer. Under normal physiological conditions, CDKs regulate the expression of genes involved in cell cycle transition. CDK2 with cyclin E and cyclin A, and CDK4 and 6 with cyclin D (CD), control G1/S cell cycle transition, whereas Cdc2 kinase with cyclin B regulates G2/M transition [159,170,171]. Silymarin and its bioactive flavonolignans significantly inhibit over-expression of these regulators and induce anti-carcinogenic activity [132,141,149,156]. It was observed from Western blot studies that silymarin impedes, in a dose-dependent manner, the gene expression of CD1 and CD2 along with a noteworthy diminution in protein expression of various CDKs in A375 cells. However, the levels of the CDK inhibitory proteins, Kip1/ p27 and Cip1/p21, were elevated after silymarin treatment [154]. Eo et al. (2015) reported that silymarin inhibits proliferation in HCT116 and SW480 cells by triggering the proteasomal degradation of CD1 at threonine-286 [132]. Moreover, Fan et al. (2014) demonstrated that silymarin dose-dependently inhibits the G1/S transition phase of the cell cycle in A2780s and PA-1 ovarian cancerous cells by altering CDK2, p53, p21 and p27 gene expressions [149]. Notably, a clinical study revealed that silymarin treatment in hepatocellular carcinoma patients also arrests the cell cycle pathway by down-regulating expression of the DNA topoisomerase 2-binding protein 1 (TOPBP1), the nucleolar and
spindle-associated protein 1 (NUSAP1) and the cell division cycle-associated 3 protein (CDC3), which are important for mitotic progression and regulation [172].

Despite inhibiting various CDK and MAPK signaling pathways, silymarin also significantly impedes various other pathways, such as the Notch pathway [141], the PI3K-PKB/Akt signaling pathway [120], the PP2Ac/AKT Ser473/mammalian target of rapamycin (mTOR) pathway [134], the Slit-2/Robo-1 signaling pathway [140,150] and the Wnt/β-catenin signaling pathway [129]. The PI3K/Akt pathway is an essential regulatory element responsible for cellular growth, proliferation and differentiation through activation of CDK-4 and CDK-2. Feng et al. (2016) reported that silybin impedes the PI3K/Akt/mTOR signaling pathway in U266 cells by down-regulating the protein expression of p-Akt, PI3K and p-mTOR [157]. Furthermore, it was shown that inhibition of PI3K/Akt pathways also restrains bladder cancer growth and progression in T24 and UM-UC-3 human bladder cancer cells [120]. The β-catenin-dependent Wnt signaling (Wnt/β-catenin signaling) pathway is also accountable for cellular proliferation, apoptosis and tissue homeostasis [173,174]. Numerous in vitro studies demonstrated silymarin anti-cancer activity via modulation of this signaling pathway [129,152]. Vaid et al. (2011) reported that silymarin treatment to A375 and Hs294t cells up-regulates expression of the glycogen synthase kinase-3β (GSK-3β) and the casein kinase 1α (CK1α), subsequently resulting in β-catenin phosphorylation and blockage of cellular migration and invasion [152]. Later on, Lu et al. (2012) observed that silymarin also modulates gene expression of the lipoprotein receptor-related protein 6 (LRP6), a critical co-receptor for the Wnt/β-catenin signaling pathway [129]. Notch 1 signaling directly activates the cyclooxygenase-2 (COX-2)/Snail/E-cadherin pathway, which subsequently induces cancerous cell invasion and migration; however, silymarin’s ability to down-regulate Notch1 prevents this cellular invasion and results in decreased cancer growth [141,175].

Matrix metalloproteinases (MMPs) degrade extracellular matrices and are accountable for metastasis and migration of cancerous cells in carcinogenesis. Silybin was reported to significantly impede MMP-2 gene expression by modulating Janus kinase-2/signal transducers and activators of the transcription-3 (Jak2/STAT3) pathway [126]. MMP plays a pivotal role in cancer metastasis, together with AP-1, through stimulation of the epithelial to mesenchymal transition of tumor cells. Down-regulating AP-1 may also serve as a possible remedial approach for cancer treatment [176]. It was reported that silybin acts as a potential anti-metastasis agent by remarkably suppressing cellular invasion by impeding AP-1 dependent MMP-9 gene expression in MCF-7 human breast carcinoma cells [127]. Recently, Si et al. (2020) found that silybin treatment elevates mitochondrial fusion through an increase in the expression of mitochondrial fusion-associated proteins (optic atrophy 1, mitofusin 1 and mitofusin 2) and down-regulation of the expression of the mitochondrial fission-associated protein (dynamin-related protein 1 (DRP1)) in MDA-MB-231 breast cancer cells, which consequently impedes cellular migration [124]. Furthermore, it was observed that silybin treatment also abolishes activation of the NLRP3 inflammasome through repression of ROS generation, resulting in reduced tumor cell migration and invasion [124]. The C-X-C chemokine receptor type in cancer cells is accountable for tumor growth, proliferation and angiogenesis [177]. Kacar et al. (2020) demonstrated that silymarin activates SLIT2 protein and suppresses C-X-C chemokine receptor type 4 expressions in DU-155 cells, thereby reducing tumor proliferation and metastasis in prostate cancer [150].

The vascular endothelial growth factor (VEGF) displays a significant role in tumor-induced angiogenesis and can be used as a hopeful target for anti-cancer therapy. Western blotting analysis demonstrated that a 500 mg/kg silymarin treatment given to mice remarkably down-regulated VEGF protein expression in the A375 tumor xenografts model [154]. Furthermore, silymarin administration was also reported to reduce CD31 expression levels, contributing to the development of new vasculature. Most interestingly, Khan et al. (2014) revealed that 9 mg/mouse topical applications of silybin significantly repress tumorigenesis and oxidative stress by down-regulating iNOS, NO, TNF-α, IL-6, IL-1β, COX-2 and
Nowadays, drug resistance to cancer therapies is a major problem in combating this disease, and various studies affirm that feedback activation of STAT-3 is majorly responsible for mediating drug resistance. However, considerable evidence suggests that silymarin can reverse STAT-3-associated cancer drug resistance by down-regulating its gene expression [178].

### 2.4. Neuroprotective Activity

Silymarin and its flavonolignans are also involved in the treatment of various neurodegenerative diseases and attenuation of the neurodegenerative alteration developed after cerebral ischemia. The main neuroprotective mechanisms of silymarin are illustrated in Figure 6. Kittur et al. (2002) demonstrated silymarin’s neurotrophic and neuroprotective effects via augmentation of nerve growth factor (NGF)-mediated neurite outgrowth in PC-12 neural cells and protection against oxidative stress-triggered cell death in rat hippocampal neurons [179]. Nitrosative stress, oxidative stress and neuroinflammation are indeed imperative pathological traits of various neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases [112,180]. Silymarin treatment significantly suppresses neuronal oxidative stress and neuroinflammation by increasing numerous exogenous enzymatic activities and attenuating inflammatory responses, respectively, as discussed in Table 5 [181–187]. Recently, it was also observed that silymarin intake prevents glutamate release via inhibition of voltage-dependent Ca\(^{2+}\) channels and the ERK1/2 pathway in a rat model of kainic acid-mediated excitotoxicity [188].

![Figure 6. Various mechanisms responsible for the neuroprotective effects of silymarin.](image_url)

Parkinson’s disease is the most common neurodegenerative disorder and is characterized by progressive loss of dopaminergic neurons with pervasive intracellular aggregation of the \(\alpha\)-synuclein protein in the substantia nigra pars compacta causing irregularities in motor behavior [189,190]. Silymarin displays potential anti-Parkinson activity by upholding striatal dopamine levels via inhibition of apoptosis and protection of dopamine...
neurons in the substantia nigra [191,192]. Srivastava et al. (2017) reported that silymarin treatment reduces α-synuclein protein levels through modification in mRNA expression of various α-synuclein suppressive genes in a Caenorhabditis elegans transgenic model [193]. Moreover, silymarin’s ability to hamper monoamine oxidase-B (MAO-B) enzymatic activity adds to the neuroprotective mechanisms of silymarin which counteract the loss of dopamine in parkinsonism [194,195]. Most importantly, Wang et al. (2002) observed that silymarin remarkably prevents microglia (glial cell) activation by inhibiting NF-κB signaling, which furthermore impairs dopamine neuron damage and likely represents a possible mechanism for its neuroprotective activity [196]. Silymarin treatment also augments the expression of the lysosome-associated membrane protein-2 (LAMP-2A) protein and reduces p-AMPK-mediated Ulk1-dependent macroautophagy in the MPTP-induced Parkinson model [197].

Alzheimer’s disease is a progressive neurodegenerative disease exemplified by progressive amyloid-beta (Aβ) peptide aggregation, synapse and nerve destruction and acetylcholine deficiency, causing memory impairment along with functional and behavioral alterations [112,198]. Inhibition of Aβ aggregation and its associated oxidative stress, as well as acetylcholinesterase (AChE) activity, is a prospective beneficial approach that can slow or diminish the development of Alzheimer’s disease [112]. Various in vivo and in vitro experimental studies affirm that silymarin and its bioactive constituents display anti-amyloidogenic activities and are capable of impairing Aβ fibril formation and aggregation along with inhibition of AChE enzymatic activity [198–202]. The amyloid precursor protein (APP) is liable for the formation of Aβ peptides through its sequential proteolytic cleavages and has a central role in the growth of Alzheimer’s disease [203]. Yaghmaei et al. (2014) demonstrated that silymarin remarkably down-regulates APP gene expression [201]. Furthermore, it was also found that silymarin reduces Aβ-protein fibril formation in an APP transgenic animal model, indicating the role of silymarin in the inhibition of APP expression [200,202]. Oxidative stress is also extremely accountable for Aβ toxicity and displays a critical role in the pathophysiology of Alzheimer’s disease. Silymarin was found to have a protective effect against Aβ-mediated oxidative stress [199,204,205]. Zhou et al. (2016) reported that isosilybin attenuates oxidative stress-induced Aβ peptide formation in hippocampal neuronal cells, possibly via augmentation of the NRF2/ARE signaling pathways [205]. Recently, it was also found that estrogen receptors play a significant role in protection against Aβ-induced toxicity, and treatment with silymarin notably modulates estrogen receptor activity and its related signaling pathways, such as MAPK and PI3K-Akt [206,207].
Table 5. Experimental studies demonstrating the activity of silymarin on CNS.

| Pharmacological Activity                                      | Study Model                                           | Dose/Concentration Used | Possible Target Site/Mechanism of Action                                                                 | References |
|---------------------------------------------------------------|-------------------------------------------------------|--------------------------|----------------------------------------------------------------------------------------------------------|------------|
| Neuroprotective                                               | Lipopolysaccharide (LPS)-induced neuroinflammatory impairment | 25–100 mg/kg             | • Over-expression of BDNF and TrkB genes<br>• Reduction in IL1β, NF-κB and TNF-α expression               | [183]      |
|                                                              | Docetaxel-induced central and peripheral neurotoxicities | 25 and 50 mg/kg          | • Down-regulation of NF-κB, TNF-α, Bax and JNK expression<br>• Up-regulation of Nrf2, Bcl-2, CREB and HO-1 expression<br>• Reduction in the levels of GSH and SOD | [208]      |
|                                                              | STZ-induced diabetic neuropathy                       | 30, 60 mg/kg/day p.o.    | • Reduction in the levels of SGPT, SGOT, INFγ, IL-1β, IL-6, TNF-α, TBRAS and endogenous antioxidant enzymes<br>• Increase in the levels of TP and albumin | [182]      |
|                                                              | Manganese-induced neurotoxicity                       | 100 mg/kg/day i.p.       | • Reduction in AOPP, PCO, TBARS and NO levels in the cerebral cortex<br>• Elevation in antioxidant enzyme activities | [209]      |
|                                                              | Acrylamide-induced cerebellar damage                  | 160 mg/kg                | • Elevation in 5-HT and dopamine levels<br>• Reduction in MDA levels<br>• Increase in CAT and SOD levels | [210]      |
|                                                              | Ischemic surgery                                      | 200 mg/kg                | • Postponement of neuronal cell death                                                                  | [211]      |
|                                                              | Kainic acid (KA)-induced excitotoxicity               | 50–100 mg/kg             | • Suppression of synaptosomal glutamate release<br>• Inhibition of ERK1/2 activity<br>• Blockage of voltage-gated Ca²⁺ channels | [188]      |
|                                                              | Middle cerebral artery occlusion                      | —                        | • Amplification of pAkt, HIF-1α, pmtOR and Bcl-2 expression<br>• Down-regulation of Bax and NF-κB expression<br>• Activation of the Akt/mTOR signaling pathway | [212]      |
| Pharmacological Activity | Study Model | Dose/Concentration Used | Possible Target Site/Mechanism of Action | References |
|--------------------------|-------------|-------------------------|-----------------------------------------|------------|
| **Anti-Alzheimer**       |             |                         |                                         |            |
| Aβ1–42-induced Alzheimer’s | 70 and 140 mg/kg p.o. for 4 weeks | • Inhibition of amyloid plaque formation  
• Down-regulation of APP gene expression | [201] |
| APP transgenic mice and PC12 cells | 0–100 µM | • Decrease in Aβ-protein fibril formation  
• Improvement in behavioral abnormalities | [202] |
| APP/PS1 transgenic mice | 2–200 mg/kg/day | • Inhibition of AChE activity  
• Reduction in plaque formation | [200] |
| Scopolamine-induced dementia | 200–800 mg/kg p.o. for 2 weeks | • Diminution in AChE activity and MDA level  
• Restoration of dopamine and GABA activity  
• Down-regulation of GFAP and NF-κB protein expression | [199] |
| Aβ1–42-induced Alzheimer | 25–100 mg/kg | • Modulation of estrogen receptor α and β expression  
• Inhibition of MAPK and PI3K-Akt pathways | [206] |
| Aluminum chloride (AlCl3)-induced Alzheimer’s | 34 mg | • Suppression of AChE activity | [198] |
| Aβ25–35-induced Alzheimer’s | 25–100 mg/kg | • Elevation in autophagy level  
• Decrease in COX-2, NF-κB and iNOS expression  
• Elevation in IL-4 levels | [181] |
| Aβ25–35-induce oxidative stress damage in HT-22 cells | — | • Activation of the NRF2/ARE pathway | [205] |
| **Anti-Parkinson**        |             |                         |                                         |            |
| Caenorhabditis elegans transgenic model | 24.12 µg/mL | • Decrease in α-synuclein protein levels  
• Alteration in mRNA expression of α-synuclein suppressive genes  
• Elevation in dopamine levels | [193] |
| MPTP-induced parkinsonism | 40 mg/kg i.p. for 2 weeks | • Decrease in beclin-1, α-synuclein, sequestosome, p-Ulk1 and p-AMPK levels  
• Elevation in DA, LAMP-2 and p-mTOR levels | [197] |
| Pharmacological Activity          | Study Model                                      | Dose/Concentration Used          | Possible Target Site/Mechanism of Action                                                                 | References |
|----------------------------------|--------------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------|------------|
| Anti-Parkinson                   | 6-OHDA-induced neurodegeneration and parkinsonism| 100 and 200 mg/kg i.p.           | • Inhibition of TBARS formation<br>• Protection of substantia nigra                                    | [192]      |
|                                  | 6-OHDA-induced neurodegeneration and parkinsonism| 100, 200 and 300 mg/kg, i.p. for 5 days | • Improvement in motor coordination<br>• Elevation in MDA levels<br>• Reduction in CSF level of IL-1β | [185]      |
|                                  | MPTP-induced parkinsonism                         | 20–400 mg/kg, i.p.               | • Preservation of dopamine level and dopamine neurons in the substantia nigra<br>• Reduction in apoptotic cells | [191]      |
| Anti-depression                  | Olfactory bullectomized (OBX) technique           | 100–200 mg/kg                    | • Improvement in BDNF expression<br>• Reduction in MDA, IL-6, TNF-α levels and oxidative stress<br>• Elevation of dopamine levels | [184]      |
|                                  | Reserpine-induced depression                      | 0–400 mg/kg                      | • Up-regulation of BDNF and TrkB expression<br>• Improvement in neuronal stem cell proliferation<br>• Enhancement in p-ERK and p-CREB levels | [214]      |
|                                  | Aβ1–42-induced Alzheimer’s                       | 25–100 mg/kg                     | • Enhancement in BDNF and TrkB expression                                                            | [215]      |
Apart from its effect on various neurodegenerative disorders, silymarin and its constituents also help manage depression. Depression is a mood disorder characterized by an importunate feeling of unhappiness and loss of interest and is directly allied with brain-derived neurotrophic factors (BDNF) and neuroinflammation [112]. Indeed, BDNF is a neurotrophin neuronal growth, function and survival factor, and impairment in BDNF/tropomyosin receptor kinase B (TrkB) signaling is considered a potential underlying factor for depression [216,217]. Several experimental studies demonstrated that silymarin and its associated constituents elevate BDNF levels, and also impair inflammatory responses and oxidative stress, via amplification of the BDNF/TrkB pathway [183,184,214,215]. In addition to this, a study by Khoshnoodi et al. (2015) has revealed that silymarin’s capability to elevate NO levels modulates the effect of various neurotransmitters, such as serotonin, norepinephrine and dopamine, which consequently induces antidepressant-like effects [213].

Silymarin was also found to ameliorate cerebral ischemia and cerebral stroke by interrupting neurodegenerative progression and inhibiting neuronal cell death in several ischemia models [211,218,219]. Wang et al. (2012) observed that silybin treatment before permanent middle cerebral artery occlusion significantly activates the Akt/mTOR signaling pathway and induces protection against ischemic stroke. Furthermore, it was affirmed that silybin also up-regulates hypoxia-inducible factor 1α (HIF-1α) and Bcl-2 expression and down-regulates Bax and NF-κB expression in ischemic brain tissue after stroke [212].

2.5. Cardioprotective and Anti-Hypertensive Activity

Cardiovascular diseases are currently the foremost source of fatality in aged adults and are usually allied with ischemic injury [112]. However, their increasing prevalence has warranted the attention of researcher who are now seeking to generate newer solutions to curb this problem and promote cardiac health. In this regard, various in vitro and in vivo studies have been carried out that describe the cardioprotective effects of silymarin, which directly plummets the levels of MDA, lactate dehydrogenase (LDH), troponin C and creatine kinase-MB (CK-MB), which are important cardiac biomarkers [77,220,221]. Moreover, silymarin treatment also diminishes myocardial oxidative stress by elevating catalase (CAT) and superoxide dismutase (SOD) activities as well as GSH content in the heart [222]. Apart from reducing the level of cardiac enzymes, silymarin also protects the heart by arresting cardiomyocyte apoptosis. Taghiabadi et al. reported that silymarin decreases the Bax/Bcl-2 ratio, cytosolic cytochrome c content and cleaved caspase-3 levels of the heart [222]. Later on, a study by Alabdan (2015) also showed that pre-treatment with 80 mg/kg of silymarin orally could prevent hyperglycemia and myocardial injury in STZ-treated diabetic rats [77].

Notably, silymarin intake in CCl₄-intoxicated rats markedly decreases the level of VEGF, which is an important angiogenic biomarker. Furthermore, it was observed that silymarin ameliorates the level of inflammatory and immunological biomarkers, such as TNF-α, InFy, IL-6 and C-reactive protein (CRP), and marks the anti-inflammatory potency of silymarin in protection against myocardial injury [220]. Gabriélová et al. (2015) observed that 2,3-dehydroisilybin, a constituent of silymarin, remarkably increases luciferase gene expression and intracellular cAMP levels while also inducing inhibition of the phosphodiesterase enzyme in isolated neonatal rat cardiomyocytes [223].

Besides this, silymarin also plays a critical role in reducing elevated atrial blood pressure (B.P.). Silymarin significantly reduces systolic B.P., basal arterial B.P. and heart rate in both the DOCA salt and fructose-induced hypertension model. It was also observed that silymarin treatment in hypertensive rats decreases urinary K⁺ excretion and tribarbituric acid reactive substance (TBARs) levels along with an augmentation in urinary Na⁺ excretion and endogenous antioxidant enzyme levels, as mentioned in Table 6 [224,225].

2.6. Anti-Viral Activity

Viral infections are considered a menace to public health and enhance the global socioeconomic burden. Currently, the significant increase of viruses as human pathogens
and the rise of large-scale epidemic outbreaks have highlighted a demand for new anti-viral
drugs. Silymarin depicts inhibitory action against many viruses in various cell lines and
in vivo studies by targeting manifold steps of the viral life cycle, as discussed in Table 7.
Silymarin and silybin directly hinder infection of the hepatitis C virus (HCV) in cell cultures
by blocking viral entry, viral fusion, viral RNA and viral protein synthesis along with poly-
merase activity and virus transmission [56,226–229]. Silymarin may reveal an advantageous
relationship with viral hepatitis through its inhibitory potential on inflammatory processes
and the cytotoxic cascade of events triggered by viral replication [230,231]. Polyak et al.
(2007) reported that, besides impairing HCV RNA and protein expression to prevent viral
replication, silymarin also inhibits TNF-α secretion and NF-kB-dependent transcription,
thus indicating the dual anti-viral and anti-inflammatory activity of this extract [232]. Fur-
thermore, data suggest that certain bioactive components of silymarin significantly inhibit
HCV infection via modulating the Jak-STAT pathway. Moreover, an in vivo study using the
uPA+/+/SCID+/+ chimeric mice model by DebRoy et al. (2016) concluded that intravenous
(iv) monotherapy with silybin significantly inhibits HCV production and prevents the
production of various transcription regulators and inflammation-related cytokines [233].

In another work, Blaising et al. (2013) demonstrated that both silybins A and B
significantly block HCV entry into the cell through clathrin-coated pits and vesicles by
slowing HCV endosomal trafficking and inhibiting clathrin-mediated endocytosis, thereby
preventing HVC infection [234]. Consistent with the above results, it was also demonstrated
that oral concomitant treatment of silybin–vitamin E–phospholipid complex pills with PEG-
IFN and ribavirin in chronic hepatitis patients for 12 months significantly lowers the viral
load [235,236]. Furthermore, iv infusion of silymarin also displayed significant anti-HCV
activity in clinical studies [229,237]. HCV-associated liver cirrhosis and liver carcinoma
are common after liver transplantation. Clinical data also reported that silymarin and its
bioactive constituents prevent HCV reoccurrence after liver transplantation [238,239].

As in HCV infection, silybin also hinders clathrin-mediated endocytosis in the hepati-
sis B virus (HBV), thus inhibiting HBV entry into cells [240]. Apart from its anti-hepatitis
potential, silymarin possesses an anti-viral activity against other viral infections, such as
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [241], the influenza
virus [242,243], the dengue virus [244,245], the mayaro virus [246,247], the enterovirus
71 [248], the chikungunya virus [249,250], the herpes virus [251] and the human immu-
nodeficiency virus (HIV) [252,253], by similarly inhibiting viral entry, viral fusion, viral
RNA and viral protein synthesis. Some studies revealed that silymarin impairs influenza
replication dose-dependently via inhibition of mRNA synthesis [242,243]. Interestingly,
the 23-(S)-2-amino-3-phenylpropanoyl derivative of silybin also blocks viral replication by
impeding formation of the Atg5-Atg12/Atg16L complex and amplifying infection-induced
autophagy. In addition, this silybin derivative also improves MAPK/ERK/p38 and IκB
kinase (IKK) signaling pathways [243].
Table 6. Experimental studies demonstrating the effect of silymarin on the cardiovascular system.

| Study Model                        | Dose/Concentration Used               | Finding/Possible Mechanism of Action                                                                 | Reference |
|------------------------------------|---------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------|
| CCl₄-induced cardiomyopathy        | 200 mg/kg/day p.o. for 21 days         | • Reduction in CK-MB, Troponin-T, INFγ, IL-6, TNF-α, CRP and VEGF levels by silymarin                           | [220]     |
| Ischemia reperfusion-induced myocardial infarction | 100–500 mg/kg p.o. for one week       | • Significant decrease in the levels of MDA, SGOT, SGPT, LDH, CK-MB, CK and endogenous antioxidant enzymes. | [221]     |
| Acrolein-induced cardio toxicity   | 25–100 mg/kg p.o.                     | • Significant decrease in the levels of MDA, troponin T, CK-MB and endogenous antioxidant enzymes. <br> • Inhibition of apoptosis by a reduction in the Bax/Bcl-2 ratio, cytosolic cytochrome c content and cleaved caspase-3 levels in heart | [222]     |
| Isoproterenol-treated rat cardiac myocytes | 0–0.7 mM                               | • Reduction in SOD, LDH and MDA levels <br> • Up-regulation of SIRT1 and Bcl-2                                   | [254]     |
| Perfused adult rat heart model and H9c2 cells | 0.01–10 µM                             | • Elevation in luciferase gene expression and intracellular cAMP levels <br> • Inhibition of phosphodiesterase enzyme | [223]     |
| Doxorubicin-induced cardio toxicity and hepatotoxicity | 60 mg/kg p.o. for 12 days         | • Decrease in the level of SGOT, SGPT, LDH, CK-MB and endogenous antioxidant enzymes                                  | [255]     |
| DOCA salt-induced hypertension     | 300 mg/kg and 500 mg/kg, p. o. for 4 weeks | • Decrease in systolic B.P., basal arterial B.P. and heart rate <br> • Elevation in urinary Na⁺ excretion and endogenous antioxidant enzymes levels <br> • Reduction in urinary K⁺ excretion and TBARS levels | [224]     |
| Fructose-induced hypertension     | 300 mg/kg and 500 mg/kg, p. o. for 6 weeks | • Decrease in systolic B.P., basal arterial B.P. and heart rate <br> • Elevation in endogenous antioxidant enzymes levels <br> • Reduction in TBARS levels | [225]     |
Table 7. Experimental anti-viral activity of silymarin.

| Type of Viral Infection | Study Model | Dose/Concentration Used | Possible Target Site/Mechanism of Action | Reference |
|-------------------------|-------------|-------------------------|-----------------------------------------|-----------|
| Chikungunya virus       | Vero and BHK-21 cells | 50 µg/mL | • Reduction in viral replication efficacy  
                              • Down-regulation of the production of viral proteins involved in the replication | [249] |
| HCV                     | Huh 7 cells | — | • Inhibition of NS5B RNA-dependent RNA polymerase activity  
                              • Inhibition of HCV and JFH1 replication | [226] |
| HCV                     | HepG2 and Huh 7 cells | — | • Reduction in JFH-1RNA and HCV RNA production  
                              • Inhibition of MTP-dependent apoB secretion | [227] |
| HCV                     | Huh 7 and PBM cells | 20–200 µg/mL | • Stimulation of the Jak-Stat pathway  
                              • Inhibition of TNF-α secretion and NF-kB-dependent transcription  
                              • Inhibition of HCV RNA and protein expression | [232] |
| HCV                     | Huh 7.5 cells | 10.4–150 µM | • Inhibition of the clathrin-dependent pathway by inhibiting HCV endosomal trafficking and clathrin-mediated endocytosis | [234] |
| HIV                     | uPA+/+ /SCID++ chimeric mice model | 61.5, 265 and 469 mg/kg i.v. for 14 days | • Decline in HCV production  
                              • Elevation in anti-inflammatory and anti-proliferative gene expression | [233] |
| Influenza virus         | MDCK cells | 100 µg/mL | • Inhibition of mRNA synthesis | [242] |
| Influenza virus         | MDCK, A549 and Vero cells  
                              Viral infection of BALB/c mice | 25 mg/kg/day | • Activation of MAPK/ERK/p38 and IKK signaling pathways  
                              • Inhibition of viral replication and formation of the Atg5-Atg12/Atg16L complex  
                              • Enhancement in infection-induced autophagy | [243] |
| HIV                     | PBMC and CEM-T4 cells | 50–500 µM | • Inhibition of T cell mitochondrial respiration and glycolysis  
                              • Inhibition of HIV entry | [253] |
| HIV                     | TZM-bl, PBMC and CEM cells | 40–324 µM | • Inhibition of viral replication  
                              • Reduction in CD4+, CD8+ and CD19+ T cell proliferation  
                              • Blockage of activation markers on CD4+ T cells | [252] |
### Table 7. Cont.

| Type of Viral Infection | Study Model                          | Dose/Concentration Used | Possible Target Site/Mechanism of Action                                                                 | Reference |
|-------------------------|-------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------|-----------|
| Mayaro virus            | HepG2 cells                         | 3.125–1400 µg/mL        | • Decrease in MDA levels and ROS formation                                                              | [246]     |
| HBV                     | HepG2-NTCP-C4 cells                 | 0–200 µM                | • Inhibition of clathrin-mediated endocytosis and reduction in transferrin uptake                          | [240]     |
| Herpes virus            | Vero cell                           | 0–125 µg/mL             | • It reduced the IC\textsubscript{50} value to 100 µg/mL                                                 | [251]     |
| SARS-CoV-2              | Human umbilical vein endothelial cells | 5–25 µM                 | • Down-regulation of TNF-α, IL-6, MCP-1 and PAI-1 gene expressions                                       | [241]     |
|                         |                                     | 1–100 µM                | • Inhibition of M\textsuperscript{pro} (main protease)                                                  | [257]     |
Importantly, silymarin exerts its anti-HIV activity by modulating various cellular functions that are responsible for T cell activation and proliferation. Silymarin significantly reduces CD4+, CD8+ and CD19+ T cell proliferation and blocks activation markers such as HLA-DR, CD38, CCR and Ki67 on CD4+ T cells, which consequently results in fewer CD4+ T cells expressing the HIV co-receptors (the C-X-C chemokine receptor 4 and the C-C chemokine receptor 5) [252]. Furthermore, another study by McClure et al. (2014) demonstrated that silymarin disturbs T cell metabolism by impairing mitochondrial respiration and glycolysis, which is useful in combating HIV infection while simultaneously blocking viral replication [253]. Moreover, based on the dual potential of silymarin to prevent both HCV and HIV viral replication, many clinical trials have been performed using this bioactive drug for HCV/HIV coinfected patients [258–260]. Recently, in line with the above results, many clinical trials are underway to study and understand the potential prophylactic or therapeutic activity of silymarin and its bioactive flavonolignans against COVID-19 [13,241,257,261,262].

2.7. Photoprotection and Dermal Applications

Skin is the outermost protective organ of the human body, defending it from oxidants and several exogenous pollutants [263,264]. Ultraviolet (UV) radiation-induced ROS generation modulates several cellular pathways and the expression of various inflammatory cytokines that, consequently, alter epidermal cellular activity. Moreover, elevated collagenase, elastase and hyaluronidase enzymatic activities also result in photoaging [265]. Accumulating data divulged that silymarin and its bioactive compounds have a pivotal role in skincare and can be used to treat various skin disorders such as melasma, photoaging, rosacea, atopic dermatitis, psoriasis, acne and radiodermatitis, as mentioned in Tables 8 and 9.

DNA mutation and the generation of cyclobutane pyrimidine dimers (CPDs) are the common mechanisms that explain the photo-protective activity of silymarin, though it was recently reported that silymarin also repairs UVB-induced DNA damage by augmenting the expression of various nucleotide excision repair (NER) genes [266,267]. In XPA-deficient and XPA-proficient mouse models, silymarin treatment remarkably reduces sunburn/apoptotic cell counts in NER-proficient mice. However, no significant change was observed in their wild-type counterparts, thus confirming the role of NPR gene expression in silymarin-mediated photoprotection [267]. Adjacent to the NER pathway, the p53 signaling pathway plays a crucial role in photoprotection. Several experimental studies have established that regulation of p53-mediated growth arrest and DNA damage-inducible protein α (GADD45α) expression is a decisive mechanism by which silymarin protects against UVB-induced photo damage [266,268,269]. GADD45α is indeed a vital transcription factor that is mediated by p53 and which regulates apoptosis, cellular proliferation and DNA damage repair [270,271]. Additionally, Rigby et al. (2017) determined the role of p53 in UVB photoprotection using p53 heterozygous (p53+/−) and p53 knockout (p53−/−) mice. Results revealed that silybin treatment considerably reduces UVB-induced lesions in p53−/+ compared with p53 deficient mice, affirming the role of silymarin in photoprotection via p53 activation [269]. Moreover, an earlier study by Gu et al. (2005) reported that silymarin hampers JNK1/2, ERK1/2, MAPK/p38 and AKT signaling pathways during UV-induced mitogenesis and prevents skin from light damage [272]. Silymarin and its major constituents can also induce photoprotection by preventing DNA single-strand break (SSB) formation and ROS generation along with a decrease in the levels of HSP70, MMP-1 proteins and caspase-3 activation [273,274].

The anti-inflammatory, antioxidant and anti-apoptotic potential of silymarin also has a significant role in photoprotection and impairing UV-induced oxidative stress [275–278]. Juráňová et al. (2019) showed that silymarin attenuates skin inflammation by activating NF-κB and AP-1 through up-regulation of IL-8 mRNA, which consequently protects from UVB-induced light damage [279]. Silymarin also significantly prevents UV-induced apoptosis by impairing caspase-3 and 8 activity [280,281].
Table 8. Experimental studies demonstrating the dermal applications of silymarin.

| Pharmacological Activity | Study Model | Dose/Concentration Used | Possible Target Site/Mechanism of Action | Reference |
|--------------------------|-------------|-------------------------|----------------------------------------|-----------|
| Photo protective          | UV exposure | 0.1–0.2 mg/mL/kg topically | • No skin irregularity, erythema, hyperpigmentation or edema were observed | [282] |
|                          | UV exposure | —                       | • Impedes SSB production and ROS generation  
• Decreases HSP70, MMP-1 and caspase-3 level  
• Increases HO-1 level | [274] |
|                          | UV exposure in HaCaT cells | 75 µm | • Decrease in caspase-3 activation and ROS levels  
• Up-regulation of CHOP protein expression | [281] |
|                          | UVB-induced skin damage in human dermal fibroblasts | 1.6–100 µM | • Decrease in caspase-3 activation and ROS levels | [273] |
|                          | XPA-deficient mice, XPA-deficient and XPA-proficient human fibroblasts and normal human epidermal keratinocytes | 10 and 20 µg/mL | • Reduction in apoptotic cell count  
• Up-regulation of NPR gene expression | [267] |
|                          | JB6 cells and mouse skin | 100 µm | • Impediment of cell cycle progression  
• Up-regulation of GADD45α gene expression | [268] |
|                          | Human dermal fibroblasts | 100 µm | • Elevation in p53 and GADD45α gene expressions | [266] |
|                          | SKH-1 hairless mouse | 9 mg topically | • Activation of the p53 pathway | [269] |
|                          | SKH-1 hairless mice skin | 9 mg topically | • Reduction in MAPK and AKT signaling pathways  
• Elevation in the p53 signaling pathway | [272] |
| Anti-alopecia             | Human dermal papilla cells | 0–200 µM | • Elevation in luciferase enzymatic activity  
• Activation of the AKT and Wnt/β-catenin signaling pathway | [283] |
| Wound healing            | Human fibroblast cells | 4.5–36 µg/mL | • Down-regulation of COX-2 mRNA expression | [284] |
|                          | Rat wound model with full-thickness excision | 2% ointment containing 500 mg silymarin | • Reduction in redness, swelling and exudation  
• Decrease in MDA levels  
• Elevation of NO synthase expression and estradiol levels | [285] |
### Table 8. Cont.

| Pharmacological Activity | Study Model | Dose/Concentration Used | Possible Target Site/Mechanism of Action | Reference |
|--------------------------|-------------|-------------------------|----------------------------------------|-----------|
| Wound healing            | Rat wound model full-thickness cutaneous defect | 6–12 mg/mL | • Decrease in lymphocyte and macrophage counts  
• Elevation in fibrocytes count, collage fibers and fibroblasts  
• Improvement in tensile strength | [286] |
|                          | Normal human dermal fibroblasts | — | • Up-regulation of IL-8 mRNA  
• Activation of NF-κB and AP-1  
• Reduction in IL-6 and IL-8 release | [279] |
|                          | Anti-aging | 0.01–2.5 g/L | • Inhibition of collagenase and elastase enzyme activities | [287] |

### Table 9. Clinical evidence published in the previous 10 years depicting various pharmacological activities of silymarin.

| Disease | No. of Patients | Dose; Duration | Add on Therapy | Study Outcomes | Reference |
|---------|-----------------|----------------|----------------|----------------|-----------|
| Diabetes | 40 | 140 mg tid p.o.; 90 days | — | • Decrease in FBS, HbA1c, MDA, CH, TG and LDL | [80] |
|         | 40 | 140 mg tid p.o.; 45 days | — | • Reduction in FBS, SOD, MDA and hs CRP levels | [288] |
|         | 40 | 420 mg tid p.o.; 45 days | — | • Reduction in HOMA-IR, insulin, LDL CH and TG levels  
• Increase in HDL levels | [289] |
|         | 85 (diagnosed with Type 1 diabetes) | 105 mg bid p.o.; 6 months | Berberis aristata 588 mg | • Reduction in FBS, HbA1c, LDL CH and TG levels  
• Increase in HDL levels | [290] |
|         | 69 | 1000 mg/day p.o. | Berberine 210 mg/day | • Decrease in FBS, HbA1c, SGPT, SGOT, CH, TG and LDL levels | [291] |
| Dyslipidemia | 139 | 105 mg bid p.o.; 6 months | Berberis aristata 500 mg and Monacolin K 10 mg | • Reduction in FBS, LDL CH and TG levels  
• Inhibition of TNF-α and IL-6 release | [38] |
|         | 137 | 105 mg bid p.o.; 6 months | Berberis aristata 588 mg | • Reduction in FBS, insulin and HOMA-index levels  
• Improvement in lipid profile | [37] |
|         | 105 | 105 mg bid p.o.; 3 months | Berberis aristata 588 mg | • Reduction in retinol-binding protein-4 and resistin levels  
• Increase in adiponectin levels | [36] |
| Disease                                      | No. of Patients | Dose; Duration                      | Add on Therapy | Study Outcomes                                                                 | Reference |
|----------------------------------------------|-----------------|-------------------------------------|----------------|-------------------------------------------------------------------------------|-----------|
| Melasma (skin disorder)                      | 96              | 7 and 14 mg/mL cream bid topically; 4 weeks | —              | • Melasma area and severity index (MASI) reached zero after 4 weeks           | [282]     |
| Acne                                         | 20              | 1% seed oil cream bid topically      | —              | • Reduction in facial wrinkles and improvement of skin tone                    | [292]     |
| Hepatocellular carcinoma                     | 56              | —                                   | N-acetylcysteine and Selenium | • Reduction in MDA and IL-8 levels • Decrease in the number of inflammatory lesions | [293]     |
| Cisplatin-induced nephrotoxicity             | 60              | 140 mg bid p.o.; 7 days             | —              | • Decrease in BUN and creatinine levels                                       | [116]     |
| Cisplatin-induced nephrotoxicity             | 86              | 140 mg tid p.o.; 21 days            | —              | • Decrease in serum creatinine levels                                         | [115]     |
| Capecitabine-induced hand-foot syndrome      | 40 (diagnosed with G.I.T. cancer) | 1% gel bid topically; 9 weeks   | Capecitabine | • Minimizes the severity of the syndrome and impairs its incidence           | [114]     |
| Radiotherapy-induced mucositis               | 27 (Diagnosed with head and neck cancer) | 420 mg/day p.o.; 6 weeks | —              | • Significant delay in mucositis growth and progression                      | [117]     |
| Radiation-induced dermatitis                 | 40 (Diagnosed with breast cancer)   | 1% gel bid topically; 5 weeks       | —              | • Significant delay in dermatitis growth and progression                      | [118]     |
| NAFLD                                        | 81              | 280 mg bid p.o.; 90 days            | Vitamin C 120 mg, Vitamin E 40 mg, Coenzyme Q10 20 mg and Selenomethionine 83 µg | • Reduction in the levels of SGPT, SGOT, ALP and γ-GT | [294]     |
|                                             | 66              | 140 mg/day p.o.                     | —              | • Decrease in SGPT, SGOT and lipid profile levels • Reduction in FBS, serum insulin levels and HOMA index | [295]     |
|                                             | 36              | 540 mg bid. p.o.; 3 months          | Vitamin E      | • Decrease in γ-GT and fibrosis scores                                        | [296]     |
|                                             | 30              | 188 mg p.o.; 6 months               | Vitamin E and Phospholipids | • Reduction in fatty liver index levels                                        | [297]     |
|                                             | 179             | 94 mg bid. p.o.; 12 months          | Phosphatidylcholine 194 mg and Vitamin E 89 mg | • Improvement in SGPT, SGOT, γ-GT, TGF-β and MMP-2 levels | [69]      |
| Disease                              | No. of Patients | Dose; Duration          | Add on Therapy                          | Study Outcomes                                                                 | Reference |
|-------------------------------------|-----------------|-------------------------|-----------------------------------------|--------------------------------------------------------------------------------|-----------|
| **NAFLD**                           | 150             | 303 mg bid. p.o.; 6 months | Vitamin D 10 mg and Vitamin E 15 mg     | • Reduction in the levels of HOMA-IR, CH, IL-18, IL-22, CRP, IGF-II, TNF-α, TGF-β, EGFR, MMP-2 and CD-44  
  • Improvement in SGPT and γ-GT levels | [61]           |
|                                     | 62              | 303 mg bid. p.o.; 6 months | Vitamin D 10 mg and Vitamin E 15 mg     | • Decrease in levels of TBARS, SGPT, HOMA-IR, TNF-α and CRP  
  • Elevation in plasmatic levels of estrogens | [298]          |
| **NASH**                            | 64              | 210 mg/day p.o.; 8 weeks | —                                       | • Reduction in BMI and the level of SGPT and SGOT | [299]     |
|                                     | 100             | 700 mg tid; 48 weeks    | —                                       | • Decrease in fibrosis  
  • Reduction in levels of SGPT and SGOT | [300]     |
|                                     | 116             | 420 and 700 mg tid, p.o.; 48 weeks | —                                       | • Improves fibrosis | [301]     |
| **Multiple sclerosis therapy-induce liver damage** | 54 (diagnosed with remitting relapsing multiple sclerosis) | 420 mg, p.o.; 6 months | IFNβ                                   | • Reduction in SGPT, SGOT, L-17 and IFNγ  
  • Decrease in Th1 and Th17 cell population and increase in Treg cell population  
  • Increase in IL-10 and TGF-β levels | [302]     |
| **Chronic HCV infection**           | 64              | 47 mg p.o; 12 months    | Ribavirin+Peg-IFN and Vitamin E+ phospholipids | • Significant decrease in viral load and reduction in plasma markers of liver fibrosis | [236]     |
| **HIV/HCV coinfection**             | 26              | 5, 10, 15, and 20 mg/kg/day i.v.; 7 and 14 days | Ribavirin+Peg-IFN | • Reduction in HCV RNA production | [229]     |
|                                     | 154             | 420 and 700 mg tid p.o.; 24 weeks | —                                       | • Reduction in SGPT levels  
  • No change in HCV RNA levels | [56]      |
| **HIV/HCV coinfection**             | 16              | 20 mg/kg/day i.v.; 14 days | Ribavirin+Peg-IFN and Telaprevir for 12 weeks | • Reduction in HCV RNA production | [260]     |
| Disease                                                                 | No. of Patients | Dose; Duration     | Add on Therapy                                                                 | Study Outcomes                                                                 | Reference |
|------------------------------------------------------------------------|-----------------|--------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|-----------|
| Anti TB drug-induced hepatotoxicity                                     | 55              | 140 mg tid p.o.; 8 weeks | Rifampicin 10 mg/kg/day, Isoniazid 5 mg/kg/day, Ethambutol 15 mg/kg/day or Pyrazinamide 25 mg/kg/day | • Decrease in SGPT, SGOT, γ-GT, ALP and total protein levels                        | [303]     |
|                                                                        | 70              | 140 mg tid p.o.; 2 weeks | Isoniazid 5 mg/kg, Pyrazinamide 20 mg/kg, Ethambutol 15 mg/kg and/or Rifampin 10 mg/kg | • No significant hepatoprotective effect                                           | [304]     |
|                                                                        | 108             | 140 mg bid p.o.; 8 weeks | Isoniazid, Pyrazinamide, Ethambutol and/or Rifampin                             | • No significant hepatoprotective effect                                           | [305]     |
| Beta thalassemia                                                       | 49              | 140 mg tid p.o.; 9 months | Desferrioxamine                                                                | • Decrease in serum iron levels and total iron-binding capacity                   | [306]     |
|                                                                        | 25              | 420 mg/ day p.o.; 12 weeks | Desferrioxamine 40 mg/kg/day                                                   | • Reduction in TNF-α and serum neopterin levels                                    | [307]     |
|                                                                        | 40              | 140 mg tid p.o.; 6 months | Deferasirox                                                                    | • Decrease in serum ferritin levels                                               | [308]     |
|                                                                        | 22              | 420 mg/ day p.o.; 6 months | Deferasirox                                                                    | • Decrease in TGF-β, IL-23, IL-17 and IL-10 levels                                | [309]     |
|                                                                        | 80              | 420 mg/ day p.o.; 9 months | Deferiprone                                                                    | • Decrease in serum ferritin and iron level                                       | [310]     |
Notably, silymarin has also been reported as a potential candidate for the treatment of alopecia. An in vitro study on human dermal papilla cells conducted by Cheon et al. (2019) demonstrated that therapy with silybin augments the spheroid formation of dermal papilla cells and induces hair-growth properties by triggering AKT and Wnt/β-catenin signaling pathways [283]. Silymarin also plays a crucial role in wound repair and healing. Oryan et al. (2012) reported that silymarin lessens lymphocyte and macrophage cell counts along with elevation in the number of fibrocytes, collagen fibers and fibroblasts [286]. Indeed, regulation of inflammation and oxidation are also essential during wound healing. Studies reported that treatment with silymarin and its active constituents considerably reduces IL-6 and IL-8 discharge and up-regulates IL-8 mRNA expression via NF-κB and AP-1 activation [279]. Furthermore, COX and NOS also help in the progression of wound healing, and silymarin can elevate NOS expression while reducing COX-2 mRNA production [284,285].

3. Conclusions

Findings from this review indicate that silymarin is a multifunctional extract which possesses the competency to modulate various cell signaling pathways and induce diverse therapeutic activities. Silymarin is a whole mixture containing different compounds, including silybins A and B, isosilybins A and B, silychristin and silydianin. Silybin is quantitatively the main component of silymarin. Thus, the literature has mainly focused on this compound while ignoring all other components. This leads to problems in reproducibility of the scientific results. Thus, further studies should individually address the main constituents of this mixture which are responsible for the biological activity and determine potential neutral, synergistic and antagonistic effects between these compounds. The inclusion of purified constituents from the silymarin mixture is needed to clarify the bioactivities of the respective compounds in future studies. Moreover, recent advancements in isolation and identification of phytochemicals have also drawn increased attention to the application of herbal medicines as potential targets for the management of various diseases. Silymarin portrays broad anti-inflammatory, antioxidant and pro-apoptotic properties (Figure 7) and modulates various transcription factors (NFκB, PPAR-γ, Nrf2, β-catenin, AP-1, WT-1, kLF6, IRS-1, SREBP-1c, CREB and GADD45α), growth factors such as BDNF, TGF-β and VEGF, receptors (LDL, estrogen receptor, GLP-1, Farnesyl x and Chemokine 4 and 5), signaling pathways (MAPK/ERK2/p53, Slit-2/Robo, Notch, CDK, Wnt/β-catenin P13K-PKB/Akt, mTOR, IRS-1/P13K/Akt and Jak-STAT), gene expression of apoptotic proteins (Bax, Bcl-2, Bcl-XL, Bim, Caspase 3, 8, 9, FADD and Survivin) and inflammatory cytokines (IL-1β, 2, 5, 6, 8, 12, TNFx, IFNγ, MIPα and MCP-1) while impairing several enzymes (COX-2, iNOS, SGPT, SGOT, MMP, MPO, AChE, G6Pase, MAO-B, LDH, Telomerase, FAS and CK-MB) and activating endogenous antioxidant enzymes, which are consequently accountable for the numerous biological and pharmacological activities reported for silymarin, including hepatoprotection, neuroprotection, cardioprotection and anti-cancer, anti-viral and anti-diabetic properties as evidenced through numerous studies and experimental data.

Therefore, silymarin may be employed as a potential candidate for managing and treating various diseases as a complementary and alternative medicine.
Figure 7. Functional triad of silymarin and its associated pharmacological properties.

Author Contributions: K.W.: Writing—Original Draft, Investigation; R.P.: Conceptualization, Validation, Writing—Review and Editing, Supervision; M.K.: Data Curation; S.K.: Data Curation; P.C.S.: Conceptualization, Writing—Review and Editing, Supervision; G.S.: Writing—Review and Editing, Supervision; R.V.: Writing—Review and Editing; V.M.: Writing—Review and Editing; I.S.: Writing—Review and Editing; D.K.: Writing—Review and Editing, Supervision; P.J.: Writing—Review and Editing, Supervision. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Data Availability Statement: All the associated data are available within the manuscript.

Conflicts of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Sample Availability: Samples of the compounds are available from the authors.

List of Abbreviations

- α-SMA: α-Smooth muscle actin
- γGT: Gamma-glutamyl transferase
- AChE: Acetylcholinesterase
- ALP: Alkaline phosphate
- AP-1: Activated protein-1
- APP: Amyloid precursor protein
- Aβ: Amyloid β
- BDNF: Brain-derived neurotrophic factors
- Bid: Two times a day
- CAT: Catalase
- CD: Cyclin D
- CDCA3: Cell division cycle-associated 3 protein
- CDK: Cyclin-dependent kinase
- CK1α: Casein kinase 1α
- CK-MB: Creatine kinase-MB
- COL-α1: Collagen α1
- CPDs: Cyclobutane pyrimidine dimers
- CREB: cAMP response element-binding protein
- CRP: C-reactive protein
- DM: Diabetes Mellitus
- DRP1: Dynamin-related protein 1
30. Iqbal, J.; Andleeb, A.; Ashraf, H.; Meer, B.; Mehmoood, A.; Jan, H.; Zaman, G.; Nadeem, M.; Drouet, S.; Fazal, H.; et al. Potential Antimicrobial, Antidiabetic, Catalytic, Antioxidant and ROS/RNS Inhibitory Activities of Silybum marianum Mediated Biosynthesized Copper Oxide Nanoparticles. RSC Adv. 2022, 12, 14069–14083. [CrossRef]

31. Staroverov, S.A.; Kozlov, S.V.; Fomin, A.S.; Gabalov, K.P.; Khanadeev, V.A.; Soldatov, D.A.; Domnitsky, I.Y.; Dykman, L.A.; Akchurin, S.V.; Gulyi, O.I. Synthesis of Silymarin – selenium Nanoparticle Conjugate and Examination of Its Biological Activity in Vivo. ADMET DMPK 2021, 9, 255–266. [CrossRef]

32. Silymarin | Side Effects | Dosage | Precautions | Medicine. Available online: https://www.medicoverhospitals.in/medicine/silymarin (accessed on 5 July 2022).

33. Han, Y.; Guo, D.; Chen, Y.; Chen, Y.; Tan, Z.R.; Zhou, H.H. Effect of Silymarin on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174 in Healthy Chinese Volunteers. Eur. J. Clin. Pharmacol. 2009, 65, 585–591. [CrossRef]

34. Molti, J.; Valle, M.; Miranda, C.; Cedeño, S.; Negredo, E.; Cloet, B. Effect of Milk Thistle on the Pharmacokinetics of Darunavir-Ritonavir in HIV-Infected Patients. Antimicrob. Agents Chemother. 2012, 56, 2837–2841. [CrossRef]

35. Almazroo, O.A.; Miah, M.K.; Venkataramanan, R. Drug Metabolism in the Liver. Clin. Liver Dis. 2017, 21, 1–20. [CrossRef]

36. Derosa, G.; D’Angelo, A.; Romano, D.; Fosger, A.; Maffioli, P. Berberis Aristata/Silybum marianum Fixed Combination on Lipid Profile and Insulin Secretion in Dyslipidemic Patients. Expert Opin. Biol. Ther. 2013, 13, 1495–1506. [CrossRef]

37. Derosa, G.; Chen, I.S.; Chen, Y.C.; Chou, C.H.; Chuang, R.F.; Sheen, L.Y.; Chiu, C.H. Hepatoprotection of Silymarin against Thioacetamide-Induced Liver Damage in Male Albino Wistar Rats. BMC Complement. Med. Ther. 2021, 21, 104. [CrossRef]

38. Abdel-Moneim, A.M.; Al-Kahtani, M.A.; El-Kersh, M.A.; Al-Omair, M.A. Free Radical-Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Actions of Taurine and Silymarin against CCl4 Induced Rat Liver Damage. PloS ONE 2015, 10, e0144509. [CrossRef]

39. Mengesha, T.; Sekaran, N.G.; Mepare, T. Hepatoprotective Effect of Silymarin on Fructose Induced Nonalcoholic Fatty Liver Disease in Male Albino Wistar Rats. BMC Complement. Med. Ther. 2021, 21, 104. [CrossRef]

40. Sokar, S.S.; El-Sayad, M.E.S.; Ghoneim, M.E.S.; Shebl, A.M. Combination of Sitagliptin and Silymarin Ameliorates Liver Fibrosis Induced by Carbon Tetrachloride in Rats. Biomed. Pharmacother. 2017, 89, 98–107. [CrossRef]

41. Chen, I.S.; Chen, Y.C.; Chou, C.H.; Chen, Y.; Tan, Z.R.; Zhou, H.H. Effect of Silymarin on Lipid Profile in Patients Not Tolerating Statins at High Doses. Atherosclerosis 2015, 239, 87–92. [CrossRef]

42. Abdel-Moneim, A.M.; Al-Kahtani, M.A.; El-Kersh, M.A.; Al-Omair, M.A. Free Radical-Scavenging, Anti-Inflammatory/Anti-Fibrotic and Hepatoprotective Effects of Silymarin against Thioacetamide-Induced Liver Damage in Male Albino Wistar Rats. BMC Complement. Med. Ther. 2021, 21, 104. [CrossRef]

43. Mahli, A.; Koch, A.; Czech, B.; Peterburs, P.; Lechner, A.; Haunschild, J.; Müller, M.; Hellerbrand, C. Hepatoprotective Effect of Oral Application of a Silymarin Extract in Carbon Tetrachloride-Induced Hepatotoxicity in Rats. Clin. Phytoscience 2018, 1, 5. [CrossRef]

44. Chen, I.S.; Chen, Y.C.; Chou, C.H.; Chang, R.F.; Sheen, L.Y.; Chiu, C.H. Hepatoprotection of Silymarin against Thioacetamide-Induced Chronic Liver Fibrosis. J. Sci. Food Agric. 2012, 92, 1441–1447. [CrossRef]

45. Heidarian, E.; Nouri, A. Hepatoprotective Effects of Silymarin against Diclofenac-Induced Liver Toxicity in Male Rats Based on Biochemical Parameters and Histological Study. Arch. Physiol. Biochem. 2021, 127, 112–118. [CrossRef] [PubMed]

46. Mahli, A.; Koch, A.; Czech, B.; Peterburs, P.; Lechner, A.; Haunschild, J.; Müller, M.; Hellerbrand, C. Hepatoprotective Effect of Oral Application of a Silymarin Extract in Carbon Tetrachloride-Induced Hepatotoxicity in Rats. Clin. Phytoscience 2018, 1, 5. [CrossRef]

47. Shaker, E.; Mahmoud, H.; Mnaa, S. Silymarin, the Antioxidant Component and Silybum marianum Extracts Prevent Liver Damage. Food Chem. Toxicol. 2010, 48, 803–806. [CrossRef]

48. Freitag, A.F.; Cardia, G.F.E.; Da Rocha, B.A.; Aguiar, R.P.; Silva-Comar, F.M.D.S.; Spironello, R.A.; Grespan, R.; Caparroz-Assef, S.M.; Bersani-Amado, C.A.; Cuman, R.K.N. Hepatoprotective Effect of Silymarin against Thioacetamide-Induced Liver Fibrosis. J. Sci. Food Agric. 2012, 92, 1441–1447. [CrossRef]

49. Haddad, P.S.; Haddad, Y.; Vallerand, D.; Brault, A. Antioxidant and Hepatoprotective Effects of Silymarin against Thioacetamide-Induced Liver Fibrosis. J. Viral Hepat. 2015, 21, 98–107. [CrossRef]

50. Zhu, S.Y.; Jiang, N.; Yang, J.; Tu, J.; Zhou, Y.; Xiao, X.; Dong, Y. Silybum marianum Oil Attenuates Hepatic Steatosis and Oxidative Stress in High Fat Diet-Fed Mice. Biomed. Pharmacother. 2018, 100, 191–197. [CrossRef]

51. Ou, Q.; Weng, Y.; Wang, S.; Zhao, Y.; Zhang, F.; Zhou, J.; Wu, X. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the NF-κB Pathway. Dig. Dis. Sci. 2018, 63, 3398–3408. [CrossRef] [PubMed]

52. Aghazadeh, S.; Amini, R.; Yazdanparast, R.; Ghaffari, S.H. Anti-Apoptotic and Anti-Inflammatory Effects of Silybum marianum in Treatment of Experimental Steatohepatitis. Exp. Toxicol. Pathol. 2011, 63, 569–574. [CrossRef]

53. Kim, S.H.; Oh, D.S.; Oh, J.Y.; Son, T.G.; Yuk, D.Y.; Jung, Y.S. Silymarin Prevents Restraint Stress-Induced Acute Liver Injury by Ameliorating Oxidative Stress and Reducing Inflammatory Response. Molecules 2016, 21, 443. [CrossRef] [PubMed]

54. Zhang, B.; Xu, D.; She, L.; Wang, Z.; Yang, N.; Sun, R.; Zhang, Y.; Yan, C.; Wei, Q.; Aa, J.; et al. Silybin Inhibits NLPR3 Inflammasome Assembly through the NAD+/SIRT2 Pathway in Mice with Nonalcoholic Fatty Liver Disease. FASEB J. 2018, 32, 757–767. [CrossRef] [PubMed]
55. Alaca, N.; Özbeylí, D.; Uslu, S.; Şahin, H.H.; Yiğitöörk, G.; Kurtel, H.; Öktem, G.; Yeşen, B.C. Treatment with Milk Thistle Extract (*Silybum marianum*), Ursodeoxycholic Acid, or Their Combination Attenuates Cholestatic Liver Injury in Rats: Role of the Hepatic Stem Cells. *Turkish J. Gastroenterol.* 2017, 28, 476–484. [CrossRef] [PubMed]

56. Fried, M.W.; Navarro, V.J.; Afshar, N.; Belle, S.H.; Wahed, A.S.; Hawke, R.L.; Doo, E.; Meyers, C.M.; Reddy, K.R. Effect of Silymarin (Milk Thistle) on Liver Disease in Patients with Chronic Hepatitis C Unsuccessfully Treated with Interferon Therapy: A Randomized Controlled Trial. *JAMA-J. Am. Med. Assoc.* 2012, 308, 274–282. [CrossRef]

57. Clichici, S.; Olteanu, D.; Nagy, A.L.; Oroș, A.; Filip, A.; Mircea, P.A. Silymarin Inhibits the Progression of Fibrosis in the Early Stages of Liver Injury in CCl4-Treated Rats. *J. Med. Food* 2015, 18, 290–298. [CrossRef]

58. Raghub, R.; Karthikeyan, S. Zidovudine and Isoniazid Induced Liver Toxicity and Oxidative Stress: Evaluation of Mitigating Properties of Silibinin. *Environ. Toxicol. Pharmacol.* 2016, 46, 217–226. [CrossRef] [PubMed]

59. Malaguarnera, M.; Di Rosa, M.; Nicoletti, F.; Malaguarnera, L. Molecular Mechanisms Involved in NAFLD Progression. *J. Mol. Med.* 2009, 87, 679–695. [CrossRef] [PubMed]

60. Shaarawy, S.M.; Tohamy, A.A.; Elgendy, S.M.; Abd Elmageed, Z.Y.; Bahnasy, A.; Mohamed, M.S.; Kandil, E.; Matrougui, K. Protective Effects of Garlic and Silymarin on NDEA-Induced Rats Hepatotoxicity. *Int. J. Biol. Sci.* 2009, 5, 549–557. [CrossRef]

61. Federico, A.; Dallio, M.; Masarone, M.; Gravina, A.G.; Di Sarno, R.; Tuccillo, C.; Cossiga, V.; Lama, S.; Stiuso, P.; Morisco, F.; et al. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease Patients. *Oxid. Med. Cell. Longev.* 2019, 2019, 1–12. [CrossRef]

62. Gharagozloo, M.; Jafari, S.; Esmaeil, N.; Javid, E.N.; Bagherpour, B.; Rezaei, A. Immunosuppressive Effect of Silymarin on the Expression of MMPs and TIMPs in Liver Fibrosis—a Systematic Review with Special Emphasis on Anti-Fibrotic Strategies. *J. Hepatol.* 2007, 46, 955–975. [CrossRef]

63. Sinha, K.; Das, J.; Pal, P.B.; Sil, P.C. Oxidative Stress: The Mitochondria-Dependent and Mitochondria-Independent Pathways of Apoptosis. *Arch. Toxicol.* 2013, 87, 1157–1180. [CrossRef]

64. Kisseleva, T.; Brenner, D. Molecular and Cellular Mechanisms of Liver Fibrosis and Its Regression. *Nat. Rev. Gastroenterol. Hepatol.* 2020, 18, 151–166. [CrossRef]

65. Fuchs, E.C.; Weyhenmeyer, R.; Weiner, O.H. Effects of Silibinin and of a Synthetic Analogue on Isolated Rat Hepatic Stellate Cells and Myofibroblasts. *Arzneimittel-Forschung* 1997, 47, 1383–1387. [PubMed]

66. Deshmane, S.L.; Kremlev, S.; Amini, S.; Sawaya, B.E. Monocyte Chemoattractant Protein-1 (MCP-1): An Overview. *Basic Clin. Pharmacol. Toxicol.* 2013, 103, 209–214. [CrossRef] [PubMed]

67. Tsuruta, S.; Nakamuta, M.; Enjoji, M.; Kotoh, K.; Hiasa, K.; Egashira, K.; Nawata, H. Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Prevents Dimethylnitrosamine-Induced Hepatic Fibrosis in Rats. *Int. J. Mol. Med.* 2004, 14, 837–842. [CrossRef] [PubMed]

68. Hemmann, S.; Graf, J.; Roderfeld, M.; Roeb, E. Expression of MMPs and TIMPs in Liver Fibrosis—a Systematic Review with Special Emphasis on Anti-Fibrotic Strategies. *J. Hepatol.* 2007, 46, 955–975. [CrossRef]

69. Loguerico, C.; Andreone, P.; Brisc, C.; Brisc, M.C.; Bugianesi, E.; Chiaramonte, M.; Cursaro, C.; Danila, M.; De Sio, I.; Floreani, A.; et al. Silybin Combined with Phosphatidylcholine and Vitamin e in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. *Free Radic. Biol. Med.* 2012, 52, 1658–1665. [CrossRef]

70. Dehmlov, C.; Erhard, J.; De Groot, H. Inhibition of Kupffer Cell Functions as an Explanation for the Hepatoprotective Properties of Silibinin. *Hepatology* 1996, 23, 749–754. [CrossRef]

71. Sonnenbichler, J.; Goldbero, M.; Hane, L.; Madubunyi, I.; Vogel, S.; Zett, I. Stimulatory Effect of Silybinin on the DNA Synthesis in Partially Hepatectomized Rat Livers: Non-Response in Hepatoma and Other Malign Cell Lines. *Biochem. Pharmacol.* 1986, 35, 538–541. [CrossRef]

72. Yormaz, S.; Bulbuloglu, E.; Kurutas, E.B.; Cirilik, H.; Yuzbasioglou, M.F.; Yildiz, H.; Coskuner, I.; Silay, E.; Kantarceken, B.; Goksu, M.; et al. The Comparison of the Effects of Hepatic Regeneration after Partial Hepatectomy, *Silybum Marinaum*, Propofol, N-Acetylcysteine and Vitamin E on Liver. *Brtislava Med. J.* 2012, 113, 145–151. [CrossRef]

73. Thakur, V.; Choudhary, M.; Garg, A.; Choudhary, N.; Jangra, A.; Budhwar, V. Evaluation of a Hydroalcoholic Extract of the Leaves from the Endangered Medicinal Plant *Gloriosa Superba* Linn. (Colchicaceae) for Its Potential Anti-Diabetic Effect. *Arch. Med. Sci.* 2015, 7, 1–8.

74. Sharma, S.; Wadhwa, K.; Choudhary, M.; Budhwar, V. Ethnopharmacological Perspectives of Glucokinase Activators in the Treatment of Diabetes Mellitus. *Nat. Prod. Res.* 2021, 1–15. [CrossRef] [PubMed]

75. Feng, B.; Meng, R.; Huang, B.; Shen, S.; Bi, Y.; Zhu, D. Silymarin Alleviates Hepatic Oxidative Stress and Protects against Metabolic Disorders in High-Fat Diet-Fed Mice. *Free Radic. Res.* 2016, 50, 314–327. [CrossRef] [PubMed]

76. Rahimi, R.; Karimi, J.; Khodadadi, L.; Tayebinia, H.; Kheiripour, N.; Hashemnia, M.; Goli, F. Silymarin Ameliorates Expression of Urotensin II (U-II) and Its Receptor (UTR) and Attenuates Toxic Oxidative Stress in the Heart of Rats with Type 2 Diabetes. *Biomed. Pharmacother.* 2018, 101, 244–250. [PubMed]

77. Alabdan, M.A. Silymarin Ameliorates Metabolic Risk Factors and Protects against Cardiac Apoptosis in Streptozocin-Induced Diabetic Rats. *Biomed. Biotechnol.* 2015, 3, 20–27. [CrossRef]

78. Abu-zaiton, A.S. Evaluating the Effect of *Silybum marianum* Extract on Blood Glucose, Liver and Kidney Functions in Diabetic Rats. *Adv. Stud. Biol.* 2013, 5, 447–454. [CrossRef]
79. Gu, M.; Zhao, P.; Huang, J.; Zhao, Y.; Wang, Y.; Li, Y.; Li, Y.; Fan, S.; Ma, Y.M.; Tong, Q.; et al. Silymarin Ameliorates Metabolic Dysfunction Associated with Diet-Induced Obesity via Activation of Farnesyl X Receptor. *Front. Pharmacol.* 2016, 7, 345. [CrossRef]

80. Talaat Elgarf, A.; Maher Mahdy, M.; Sabri, N.A. Effect of Silymarin Supplementation on Glycemic Control, Lipid Profile and Insulin Resistance in Patients with Type 2 Diabetes Mellitus. *Int. J. Adv. Res.* 2015, 3, 812–821.

81. Numan, A.T.; Hadi, N.A.; Sh Mohammed, N.; Hussain, S.A. Use of Silymarine as Adjuvant in Type 1 Diabetes Mellitus Patients Poorly Controlled with Insulin. *J. Fac. Med. Baghdad* 2010, 52, 75–79. [CrossRef]

82. Velussi, M.; Cernigoi, A.M.; Ariella, D.M.; Dapas, F.; Caffau, C.; Zilli, M. Long-Term (12 Months) Treatment with an Anti-Oxidant Drug (Silymarin) Is Effective on Hyperinsulinemia, Exogenous Insulin Need and Malondialdehyde Levels in Cirrhotic Diabetic Patients. *J. Hepatol.* 1997, 26, 871–879. [CrossRef]

83. Huseini, H.F.; Larijani, B.; Heshmat, R.; Fakhhrzadeh, H.; Radjabipour, B.; Toliat, T.; Raza, M. The Efficacy of *Silybum marianum* (L.) Gaertn. (Silymarin) in the Treatment of Type II Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. *Phyther. Res.* 2006, 20, 1036–1039. [CrossRef]

84. Hussain, S.A.R. Silymarin as an Adjunct to Glibenclamide Therapy Improves Long-Term and Postprandial Glycemic Control and Body Mass Index in Type 2 Diabetes. *J. Med. Food* 2007, 10, 543–547. [CrossRef]

85. Guigas, B.; Nabouts, R.; Villanueva, G.R.; Taleux, N.; Lopez-Novoa, J.M.; Leverve, X.M.; El-Mir, M.Y. The Flavonoid Silibinin Decreases Glucose-6-Phosphate Hydrolysis in Perfused Rat Hepatocytes by an Inhibitory Effect on Glucose-6-Phosphatase. *Cell. Physiol. Biochem.* 2007, 20, 925–934. [PubMed][CrossRef]

86. Feng, B.; Huang, B.; Jing, Y.; Shen, S.; Feng, W.; Wang, W.; Meng, R.; Zhu, D. Silymarin Ameliorates the Disordered Glucose Metabolism of Mice with Diet-Induced Obesity by Activating the Hepatic SIRT1 Pathway. *Cell. Signal.* 2021, 84, 110023. [CrossRef][PubMed]

87. Guo, Y.; Wang, S.; Wang, Y.; Zhu, T. Silymarin Improved Diet-Induced Liver Damage and Insulin Resistance by Decreasing Inflammation in Mice. *Pharm. Biol.* 2016, 54, 2995–3000. [CrossRef][PubMed]

88. Soto, C.; Raya, L.; Juárez, J.; Pérez, J.; González, I. Effect of Silymarin in Pdx-1 Expression and the Proliferation of Pancreatic β-Cells in a Pancreatectomy Model. *Phytomedicine* 2014, 21, 233–239. [CrossRef]

89. Qin, N.; Hu, X.; Li, S.; Wang, J.; Li, Z.; Li, D.; Xu, F.; Gao, M.; Hua, H. Hypoglycemic Effect of Silichristin A from *Silybum marianum* Fruit via Protecting Pancreatic Islet β Cells from Oxidative Damage and Inhibiting α-Glucosidase Activity In Vitro and in Rats with Type 1 Diabetes. *J. Funct. Foods* 2017, 38, 168–179. [CrossRef]

90. Xu, F.; Yang, J.; Negishi, H.; Sun, Y.; Li, D.; Zhang, X.; Hayashi, T.; Gao, M.; Ikeda, K.; Ikejima, T. Silibinin Decreases Hepatic Glucose Production through the Activation of Gut–Brain–Liver Axis in Diabetic Rats. *Food Funct.* 2018, 9, 4926–4935. [CrossRef]

91. Amniattalab, A.; Malekeinjad, H.; Rezabaksh, A.; Rokhsartalab-Azar, S.; Alizade-Fanalou, S. Silymarin: A Novel Natural Agent to Restore Defective Pancreatic β Cells in Streptozotocin (STZ)-Induced Diabetic Rats. *Iran. J. Pharm. Res.* 2016, 15, 493–500. [CrossRef]

92. Malekeinjad, H.; Rezabaksh, A.; Rahmani, F.; Hobbenaghi, R. Silymarin Regulates the Cytochrome P450 3A2 and Glutathione Peroxides in the Liver of Streptozotocin-Induced Diabetic Rats. *Phytomedicine* 2012, 19, 583–590. [CrossRef]

93. Kim, E.J.; Kim, J.; Lee, M.Y.; Sudhanva, M.S.; Devakumar, S.; Jeon, Y.J. Silymarin Inhibits Cytokine-Stimulated Pancreatic Beta Cells by Blocking the ERK1/2 Pathway. *Biomol. Ther.* 2014, 22, 282–287. [CrossRef]

94. Soto, C.; Raya, L.; Pérez, J.; González, I.; Pérez, S. Silymarin Induces Expression of Pancreatic Nkx6.1 Transcription Factor and β-Cells Neogenesis in a Pancreatectomy Model. *Molecules* 2014, 19, 4654–4668. [PubMed][CrossRef]

95. Li, H.B.; Yang, Y.R.Y.; Mo, Z.J.; Ding, Y.; Jiang, W.J. Silibinin Improves Palmitate-Induced Insulin Resistance in C2C12 Myotubes by Attenuating IRS-1/PI3K/Akt Pathway Inhibition. *Braz. J. Med. Biol. Res.* 2015, 48, 440–446. [CrossRef][PubMed]

96. Yang, J.; Sun, Y.; Xu, F.; Liu, W.; Hayashi, T.; Onodera, S.; Tashiro, S.I.; Ikejima, T. Involvement of Estrogen Receptors in Silibinin Protection of Pancreatic β-Cells from TNFα- or IL-1β-Induced Cytotoxicity. *Biomed. Pharmacother.* 2018, 102, 344–353. [CrossRef][PubMed]

97. Sun, Y.; Yang, J.; Liu, W.; Yao, G.; Xu, F.; Hayashi, T.; Onodera, S.; Ikejima, T. Attenuating Effect of Silymarin on Palmitic Acid-Induced Apoptosis and Mitochondrial Dysfunction in Pancreatic β-Cells Is Mediated by Estrogen Receptor Alpha. *Mol. Cell. Biochem.* 2019, 460, 81–92. [CrossRef]

98. Wang, J.; Zhang, X.; Zhang, L.; Yan, T.; Wu, B.; Xu, F.; Jia, Y. Silichristin A Activates Nr2-1/POK/ActR Pathway to Reduce Apoptosis and Improve GLP-1 Production through Upregulation of Estrogen Receptor α in GLUTag Cells. *Eur. J. Pharmacol.* 2020, 881, 173236. [CrossRef]

99. Stolf, A.M.; Cardoso, C.C.; Acco, A. Effects of Silymarin on Diabetes Mellitus Complications: A Review. *Phyther. Res.* 2017, 31, 366–374. [CrossRef]

100. Tuorkey, M.J.; El-Desouki, N.I.; Kamel, R.A. Cytoprotective Effect of Silymarin against Diabetes-Induced Cardiomyocyte Apoptosis in Diabetic Rats. *Biomed. Environ. Sci.* 2015, 28, 36–43. [CrossRef]

101. Meng, S.; Yang, F.; Wang, Y.; Qin, Y.; Xian, H.; Che, H.; Wang, L. Silymarin Ameliorates Diabetic Cardiomyopathy via Inhibiting TGF-B1/Smad Signaling. *Cell Biol. Int.* 2019, 43, 65–72. [CrossRef]

102. Sheela, N.; Jose, M.A.; Sathyamurthy, D.; Kumar, B.N. Effect of Silymarin on Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Nephropathy in Rats. *Iran. J. Kidney Dis.* 2013, 7, 117–123.
127. Lee, S.O.; Jeong, Y.J.; Im, H.G.; Kim, C.H.; Chang, Y.C.; Lee, I.S. Silybin Suppresses PMA-Induced MMP-9 Expression by Blocking the AP-1 Activation via MAPK Signaling Pathways in MCF-7 Human Breast Carcinoma Cells. Biochem. Biophys. Res. Commun. 2007, 354, 165–171. [CrossRef]

128. Kim, S.; Choi, J.H.; Lim, H.I.; Lee, S.K.; Kim, W.W.; Kim, J.S.; Kim, J.H.; Choe, J.H.; Yang, J.H.; Nam, S.J.; et al. Silybin Prevents TPA-Induced MMP-9 Expression and VEGF Secretion by Inactivation of the Raf/MEK/ERK Pathway in MCF-7 Human Breast Cancer Cells. Phytomedicine 2009, 16, 573–580. [CrossRef]

129. Lu, W.; Lin, C.; King, T.D.; Chen, H.; Reynolds, R.C.; Li, Y. Silybin Inhibits Wnt/β-Catenin Signaling by Suppressing Wnt Co-Receptor LRP6 Expression in Human Prostate and Breast Cancer Cells. Cell. Signal. 2012, 24, 2291–2296. [CrossRef]

130. Kauntz, H.; Bousserouel, S.; Gossé, F.; Marescaux, J.; Raul, F. Silybin, a Natural Flavonoid, Modulates the Early Expression of Chemoprevention Biomarkers in a Preclinical Model of Colon Carcinogenesis. Int. J. Oncol. 2012, 41, 849–854. [CrossRef]

131. Kauntz, H.; Bousserouel, S.; Gossé, F.; Raul, F. Silybin Triggers Apoptotic Signaling Pathways and Autophagic Survival Response in Human Colon Adenocarcinoma Cells and Their Derived Metastatic Cells. Apoptosis 2011, 16, 1042–1053. [CrossRef]

132. Eo, H.J.; Park, G.H.; Song, H.M.; Lee, J.W.; Kim, M.K.; Lee, M.H.; Lee, J.R.; Koo, J.S.; Jeong, J.B. Silymarin Induces Cyclin D1 Proteosomal Degradation via Its Phosphorylation of Threonine-286 in Human Colorectal Cancer Cells. Int. Immunopharmacol. 2015, 24, 1–6. [CrossRef]

133. Eo, H.J.; Jeong, J.B.; Koo, J.S.; Jeong, H.J. Silymarin-Mediated Degradation of c-Myc Contributes to the Inhibition of Cell Proliferation in Human Colorectal Cancer Cells. Korean J. Plant Resour. 2017, 30, 265–271. [CrossRef]

134. Wang, J.Y.; Chang, C.C.; Chiang, C.C.; Chen, W.M.; Hung, S.C. Silybin Suppresses the Maintenance of Colorectal Cancer Stem-like Cells by Inhibiting PP2A/AKT/MTOR Pathways. J. Cell. Biochem. 2012, 113, 1733–1743. [CrossRef]

135. Kim, S.H.; Choo, G.S.; Yoo, E.S.; Woo, J.S.; Han, S.H.; Lee, J.H.; Jang, J.Y. Silymarin Induces Inhibition of Growth and Apoptosis through Modulation of the MAPK Signaling Pathway in AGS Human Gastric Cancer Cells. Oncol. Rep. 2019, 42, 1904–1914. [CrossRef]

136. Li, R.; Yu, J.; Wang, C. Silibinin Promotes the Apoptosis of Gastric Cancer BGC823 Cells through Caspase Pathway. J. BUON 2017, 22, 1148–1153. [PubMed]

137. Wang, Y.X.; Cai, H.; Jiang, G.; Zhou, T.B.; Wu, H. Silibinin Inhibits Proliferation, Induces Apoptosis and Causes Cell Cycle Arrest in Human Gastric Cancer MGC803 Cells via STAT3 Pathway Inhibition. Asian Pac. J. Cancer Prev. 2014, 15, 6791–6798. [CrossRef][PubMed]

138. Zappavigna, S.; Vanacore, D.; Lama, S.; Potenza, N.; Russo, A.; Ferranti, P.; Dallio, M.; Federico, A.; Loguercio, C.; Sperlongano, P.; et al. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and Mirnas Secretion in Human Hepatocarcinoma Cells. Int. J. Mol. Sci. 2019, 20, 2190. [CrossRef][PubMed]

139. Guo, S.; Bai, X.; Liu, Y.; Shi, S.; Wang, X.; Zhan, Y.; Kang, X.; Chen, Y.; An, H. Inhibition of TMEM16A by Natural Product Silibinin: Decreased the Expressions of Matrix Metalloproteinases-2 and 9 in Rat Liver Carcinogenesis. Invest. New Drugs 2009, 27, 233–240. [CrossRef][PubMed]

140. Faezizadeh, Z.; Mesbah-Namin, S.A.R.; Allameh, A. The Effect of Silymarin on Telomerase Activity in the Human Leukemia Cell Line K562. Planta Med. 2012, 78, 899–902. [CrossRef][PubMed]

141. Guo, S.; Bai, X.; Liu, Y.; Shi, S.; Wang, X.; Zhan, Y.; Kang, X.; Chen, Y.; An, H. Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Front. Pharmacol. 2021, 12, 736. [CrossRef][PubMed]

142. Zhang, S.; Yang, Y.; Liang, Z.; Duan, W.; Yang, J.; Yan, J.; Wang, N.; Feng, W.; Ding, M.; Nie, Y.; et al. Silybin-Mediated Inhibition of Notch Signaling Exerts Antitumor Activity in Human Hepatocellular Carcinoma Cells. PLoS ONE 2013, 8, e83699. [CrossRef][PubMed]

143. Ramakrishnan, G.; Jagan, S.; Kamaraj, S.; Anandakumar, P.; Devaki, T. Silymarin Attenuated Mast Cell Recruitment Thereby Decreased the Expressions of Matrix Metalloproteinases-2 and 9 in Rat Liver Carcinogenesis. Invest. New Drugs 2009, 27, 233–240. [CrossRef][PubMed]

144. Faeezizadeh, Z.; Mesbah-Namin, S.A.R.; Allameh, A. The Effect of Silymarin on Telomerase Activity in the Human Leukemia Cell Line K562. Planta Med. 2012, 78, 899–902. [CrossRef][PubMed]

145. Guo, S.; Bai, X.; Liu, Y.; Shi, S.; Wang, X.; Zhan, Y.; Kang, X.; Chen, Y.; An, H. Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma. Front. Pharmacol. 2021, 12, 736. [CrossRef][PubMed]

146. Won, D.H.; Kim, L.H.; Jang, B.; Yang, I.H.; Kwon, H.J.; Jin, B.; Oh, S.H.; Kang, J.H.; Hong, S.D.; Shin, J.A.; et al. In Vitro and In Vivo Anti-Cancer Activity of Silibinin on Oral Cancer. Tumor Biol. 2018, 40, 101042831776170. [CrossRef][PubMed]

147. Choi, E.S.; Oh, S.; Jang, B.; Yu, H.J.; Shin, J.A.; Cho, N.P.; Yang, I.H.; Won, D.H.; Kwon, H.J.; Hong, S.D.; et al. Silybin and Its Active Component Silibinin Act as Novel Therapeutic Alternatives for Salivary Gland Cancer by Targeting the ERK1/2-Bim Signaling Cascade. Cell. Oncol. 2017, 40, 235–246. [CrossRef][PubMed]

148. Nyugen, R.M.; Devaraj, E. Silybin Triggers the Mitochondrial Pathway of Apoptosis in Human Oral Squamous Carcinoma Cells. Asian Pac. J. Cancer Prev. 2020, 21, 1877–1882. [CrossRef][PubMed]

149. Fan, L.; Ma, Y.; Liu, Y.; Zheng, D.; Huang, G. Silymarin Induces Cell Cycle Arrest and Apoptosis in Ovarian Cancer Cells. Eur. J. Pharmacol. 2014, 743, 79–88. [CrossRef][PubMed]

150. Kacar, S.; Bektur Aykanat, N.E.; Sahinturk, V. Silymarin Inhibited DU145 Cells by Activating SLIT2 Protein and Suppressing Expression of CXCR4. Med. Oncol. 2020, 37, 18. [CrossRef][PubMed]
178. Bosch-Barrera, J.; Queralt, B.; Menendez, J.A. Targeting STAT3 with Silibinin to Improve Cancer Therapeutics. *Cancer Treat. Rev.* 2017, 58, 61–69. [CrossRef] [PubMed]

179. Kittur, S.; Wilasrusmee, S.; Pedersen, W.A.; Mattson, M.P.; Straube-West, K.; Wilasrusmee, C.; Jubelt, B.; Kittur, D.S. Neurotrophic and Neuroprotective Effects of Milk Thistle (*Silybum marianum*) on Neurons in Culture. *J. Mol. Neurosci.* 2002, 18, 265–269. [CrossRef]

180. Darvesh, A.S.; Carroll, R.T.; Bishayee, A.; Geldenhuys, W.J.; Van Der Schyf, C.J. Oxidative Stress and Alzheimer’s Disease: Dietary Polyphenols as Potential Therapeutic Agents. *Expert Rev. Neurother.* 2010, 10, 729–745. [CrossRef]

181. Song, X.; Zhou, B.; Lei, D.; Zhang, P.; Yao, G.; Xia, M.; Hayashi, T.; Hattori, S.; Ushiki-Kaku, Y.; et al. Silibinin Ameliorates Aβ25-35-Induced Memory Deficits in Rats by Modulating Autophagy and Attenuating Neuroinflammation as Well as Oxidative Stress. *Neurochem. Res.* 2017, 42, 1073–1083. [CrossRef]

182. Al-Enazi, M.M. Neuroprotective Effect of Silymarin by Modulation of Endogenous Biomarkers in Streptozotocin Induced Painful Diabetic Neuropathy. *Br. J. Pharmacol.* 2013, 4, 110–120. [CrossRef]

183. Song, X.; Zhou, B.; Zhang, P.; Lei, D.; Wang, Y.; Yao, G.; Hayashi, T.; Xia, M.; Tashiro, S.I.; Onodera, S.; et al. Protective Effect of Silibinin on Learning and Memory Impairment in LPS-Treated Rats via ROS–BDNF–TrkB Pathway. *Neurochem. Res.* 2016, 41, 1662–1672. [CrossRef]

184. Thakare, V.N.; Aswar, M.K.; Kulkaarni, Y.P.; Patil, R.R.; Patel, B.M. Silymarin Ameliorates Experimentally Induced Depressive like Behavior in Rats: Involvement of Hippocampal BDNF Signaling, Inflammatory Cytokines and Oxidative Stress Response. *Physiol. Behav.* 2017, 179, 401–410. [CrossRef]

185. Haddadi, R.; Nayebi, A.M.; Farajniya, S.; Brooshghalan, S.E.; Sharifi, H. Silymarin Improved 6-OHDA-Induced Motor Impairment in Hemi-Parkinsonian Rats: Behavioral and Molecular Study. *DARU J. Pharm. Sci.* 2014, 22, 38. [CrossRef] [PubMed]

186. Galhardi, F.; Mesquita, K.; Monserrat, J.M.; Barros, D.M. Effect of Silymarin on Biochemical Parameters of Oxidative Stress in Aged and Young Rat Brain. *Food Chem. Toxicol.* 2009, 47, 2655–2660. [CrossRef] [PubMed]

187. Nencini, C.; Giorgi, G.; Micheli, L. Protective Effect of Silymarin on Oxidative Stress in Rat Brain. *Phytotherapy Research* 2007, 14, 129–135. [CrossRef] [PubMed]

188. Lu, C.W.; Lin, T.Y.; Chiu, K.M.; Lee, M.Y.; Huang, J.H.; Wang, S.J. Silymarin Inhibits Glutamate Release and Prevents against Kainic Acid-Induced Excitotoxic Injury in Rats. *Biomedicines* 2020, 8, 486. [CrossRef]

189. Ullah, H.; Khan, H. Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing. *Front. Pharmacol.* 2018, 9, 422. [CrossRef]

190. Thome, A.D.; Harms, A.S.; Volpicelli-Daley, L.A.; Standaert, D.G. MicroRNA-155 Regulates Alpha-Synuclein-Induced Inflammation Responses in Models of Parkinson’s Disease. *J. Neurosci.* 2016, 36, 2383–2390. [CrossRef]

191. Pérez-H; J., Carrillo-S, C., Garcia, E., Ruiz-Mar, G., Pérez-Tamayo, R., Chavarria, A. Neuroprotective Effect of Silymarin in a MPTP Mouse Model of Parkinson’s Disease. *Toxicology 2014*, 319, 38–43. [CrossRef]

192. Baluchnejadmojarad, T.; Rnghani, M.; Mafahkeri, M. Neuroprotective Effect of Silymarin in 6-Hydroxydopamine Hemi-Parkinsonian Rat: Involvement of Estrogen Receptors and Oxidative Stress. *Neurosci. Lett.* 2010, 480, 206–210. [CrossRef]

193. Srivastava, S.; Sammi, S.R.; Laxman, T.S.; Pant, A.; Nagar, A.; Trivedi, S.; Bhatia, R.S.; Tandon, S.; Pandey, R. Silymarin Promotes Longevity and Alleviates Parkinson’s Associated Pathologies in Caenorhabditis Elegans. *J. Funct. Foods* 2017, 31, 32–43. [CrossRef]

194. Mazzio, E.A.; Harris, N.; Soliman, K.F.A. Food Constituents Attenuate Monoamine Oxidase Activity and Peroxide Levels in C6 Astrocyte Cells. *Planta Med.* 1998, 64, 603–606. [CrossRef]

195. de Oliveira, D.R.; Schaffer, L.F.; Busanello, A.; Barbosa, C.P.; Peraza, L.R.; de Freitas, C.M.; Krum, B.N.; Bressan, G.N.; Boligon, A.A.; Athayde, M.L.; et al. Silymarin Has Antioxidant Potential and Changes the Activity of Na+/K+−ATPase and Monoamine Oxidase In Vitro. *Ind. Crops Prod.* 2015, 70, 347–355. [CrossRef]

196. Wang, M.J.; Wang, W.W.; Chen, H.L.; Chang, Y.H.; Ou, H.C.; Kuo, J.S.; Hong, J.S.; Jeng, K.C.G. Silymarin Protects Dopaminergic Neurons against Lipopolysaccharide-Induced Neurotoxicity by Inhibiting Microglia Activation. *Eur. J. Neurosci.* 2002, 16, 2103–2112. [CrossRef] [PubMed]

197. Tripathi, M.K.; Rasheed, M.S.U.; Mishra, A.K.; Patel, D.K.; Singh, M.P. Silymarin Protects against Impaired Autophagy Associated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism. *J. Mol. Neurosci.* 2020, 70, 276–283. [CrossRef] [PubMed]

198. Aboelwafa, H.R.; El-Kott, A.F.; Abd-Ella, E.M.; Yousef, H.N. The Possible Neuroprotective Effect of Silymarin against Aluminum Chloride-Promoted Alzheimer’s-like Disease in Rats. *Brain Sci.* 2020, 10, 628. [CrossRef]

199. El-Marasy, S.A.A.; Abd-Elsalam, R.M.; Ahmed-Farid, O.A. Ameliorative Effect of Silymarin on Scopolamine-Induced Dementia in Rats. *Open Access Maced. J. Med. Sci.* 2015, 401–410. [CrossRef]

200. Urata, N.M.; Urakami, K.M.; Zawa, Y.O.; Inoshita, N.K.; Rie, K.I.; Shirasawa, T.; Shimizu, T. Silymarin Ameliorated Amyloid β Plaque Burden and Improved Behavioral Abnormalities in an Alzheimer’s Disease Mouse Model. *Biosci. Biotecnol. Biochem.* 2010, 74, 2299–2306. [CrossRef] [PubMed]
247. Ferraz, A.C.; Almeida, L.T.; da Silva Caetano, C.C.; da Silva Menegatto, M.B.; Souza Lima, R.L.; de Senna, J.P.N.; de Oliveira Low, Z.X.; OuYong, B.M.; Hassandarvish, P.; Poh, C.L.; Ramanathan, B. Antiviral Activity of Silymarin and Baicalein against 

245. Camini, F.C.; da Silva, T.F.; da Silva Caetano, C.C.; Almeida, L.T.; Ferraz, A.C.; Alves Vitoreti, V.M.; de Mello Silva, B.; de Queiroz

243. Song, J.H.; Choi, H.J. Silymarin Efficacy against Influenza A Virus Replication. 

242. Biermer, M.; Berg, T. Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin plus Ribavirin. 

241. Blaising, J.; Lévy, P.L.; Condeau, C.; Pihl, J.; Varbanov, M.; Teissier, E.; Ruggiero, F.; Poljak, S.J.; Oberlies, N.H.; Ivanovic, T.; et al. Silibinin Inhibits Hepatitis C Virus Entry into Hepatocytes by Inhibiting Clathrin-Dependent Trafficking. Cell. Microbiol. 2013, 15, 1866–1882. 

240. Speciale, A.; Muscar, A.; Molonia, M.S.; Cimino, F.; Saija, A.; Giorfó, S.V. Silibinin as Potential Tool against SARS-CoV-2: In Silico Spike Receptor-Binding Domain and Main Protease Molecular Docking Analysis, and In Vitro Endothelial Protective Effects. Phyther. Res. 2021, 35, 4616–4625. [CrossRef] 

239. Malaguñerena, G.; Bertino, G.; Chisari, G.; Motta, M.; Vecchio, M.; Caraci, F.; Greco, C.; Drago, F.; Nunnari, G.; et al. Silybin Supplementation during HCV Therapy with Pegylated Interferon-α plus Ribavirin Reduces Depression and Anxiety and Increases Work Ability. BMC Psychiatry 2016, 16, 398. [CrossRef] [PubMed] 

238. Mariño, Z.; Crespo, G.; D'Amato, M.; Brambilla, N.; Giacovelli, G.; Rovati, L.; Costa, J.; Navasa, M.; Forns, X. Intravenous Silibinin Monotherapy Shows Significant Antiviral Activity in HCV-Infected Patients in the Peri-Transplantation Period. J. Hepatol. 2013, 58, 412–420. [CrossRef] [PubMed] 

237. Biermer, M.; Lévy, P.L.; Condeau, C.; Pihl, J.; Varbanov, M.; Teissier, E.; Ruggiero, F.; Poljak, S.J.; Oberlies, N.H.; Ivanovic, T.; et al. Silibinin Inhibits Hepatitis C Virus Entry into Hepatocytes by Inhibiting Clathrin-Dependent Trafficking. Cell. Microbiol. 2013, 15, 1866–1882. 

236. Malaguñerena, G.; Bertino, G.; Chisari, G.; Motta, M.; Vecchio, M.; Vacante, M.; Caraci, F.; Greco, C.; Drago, F.; Nunnari, G.; et al. Silybin Supplementation during HCV Therapy with Pegylated Interferon-α plus Ribavirin Reduces Depression and Anxiety and Increases Work Ability. BMC Psychiatry 2016, 16, 398. [CrossRef] [PubMed] 

235. Malaguñerena, G.; Bertino, G.; Chisari, G.; Motta, M.; Vecchio, M.; Caraci, F.; Greco, C.; Drago, F.; Nunnari, G.; et al. Silybin Supplementation during HCV Therapy with Pegylated Interferon-α plus Ribavirin Reduces Depression and Anxiety and Increases Work Ability. BMC Psychiatry 2016, 16, 398. [CrossRef] [PubMed] 

234. Blaising, J.; Lévy, P.L.; Condeau, C.; Pihl, J.; Varbanov, M.; Teissier, E.; Ruggiero, F.; Poljak, S.J.; Oberlies, N.H.; Ivanovic, T.; et al. Silibinin Inhibits Hepatitis C Virus Entry into Hepatocytes by Inhibiting Clathrin-Dependent Trafficking. Cell. Microbiol. 2013, 15, 1866–1882. 

233. Malaguñerena, G.; Bertino, G.; Chisari, G.; Motta, M.; Vecchio, M.; Vacante, M.; Caraci, F.; Greco, C.; Drago, F.; Nunnari, G.; et al. Silybin Supplementation during HCV Therapy with Pegylated Interferon-α plus Ribavirin Reduces Depression and Anxiety and Increases Work Ability. BMC Psychiatry 2016, 16, 398. [CrossRef] [PubMed] 

232. Malaguñerena, G.; Bertino, G.; Chisari, G.; Motta, M.; Vecchio, M.; Malaguñerena, G.; Caraci, F.; Nunnari, G.; Gagliano, C.; Greco, C.; Chisari, G.; Drago, F.; et al. Silybin-Vitamin E-Phospholipids Complex Reduces Liver Fibrosis in Patients with Chronic Hepatitis C Treated with Pegylated Interferon α and Ribavirin. Am. J. Transl. Res. 2015, 7, 2510–2518. 

231. Sabir, S.; Arshad, M.; Asif, S.; Chaudhari, S.K. An Insight into Medicinal and Therapeutic Potential of Silybum marianum (L.) Gaertn. Int. J. Biosci. 2014, 4, 104–115. [CrossRef] 

230. Sabir, S.; Arshad, M.; Asif, S.; Chaudhari, S.K. An Insight into Medicinal and Therapeutic Potential of Silybum marianum (L.) Gaertn. Int. J. Biosci. 2014, 4, 104–115. [CrossRef] 

229. Anthony, K.; Subramanya, G.; Uprichard, S.; Hammouda, F.; Saleh, M. Antioxidant and Antiviral Activity of Silymarin in Comparison with Baicalein against EV-A71. 

228. Anthony, K.; Subramanya, G.; Uprichard, S.; Hammouda, F.; Saleh, M. Antioxidant and Antiviral Activity of Silymarin in Comparison with Baicalein against EV-A71. 

227. Wagoner, J.; Negash, A.; Kane, O.J.; Martinez, L.E.; Nahmias, Y.; Bourne, N.; Owen, D.M.; Grove, J.; Brimacombe, C.; McKeating, J.A.; et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology 2010, 51, 1912–1921. [CrossRef] 

226. Cardile, A.P.; Mbuy, G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013, 3, 132–136. [CrossRef] 

225. Cardile, A.P.; Mbuy, G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013, 3, 132–136. [CrossRef] 

224. Cardile, A.P.; Mbuy, G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013, 3, 132–136. [CrossRef] 

223. Cardile, A.P.; Mbuy, G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013, 3, 132–136. [CrossRef] 

222. Cardile, A.P.; Mbuy, G.K.N. Anti-Herpes Virus Activity of Silibinin, the Primary Active Component of Silybum marianum. J. Herb. Med. 2013, 3, 132–136. [CrossRef]
252. McClure, J.; Lovelace, E.S.; Elahi, S.; Maurice, N.J.; Wagoner, J.; Dragavon, J.; Mittler, J.E.; Kraft, Z.; Stamatatos, L.; Horton, H.; et al. Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation. *PLoS ONE* 2012, 7, 41832. [CrossRef]

253. McClure, J.; Margineantu, D.H.; Sweet, I.R.; Polyak, S.J. Inhibition of HIV by Legalon-SIL Is Independent of Its Effect on Cellular Metabolism. *Virology* 2014, 449, 96–103. [CrossRef]

254. Zhou, B.; Wu, L.J.; Li, N.H.; Tashiro, S.I.; Onodera, S.; Uchiiumi, F.; Ikejima, T. Silibinin Protects against Isoproterenol-Induced Rat Cardiac Myocyte Injury through Mitochondrial Pathway after up-Regulation of SIRT1. *J. Pharmacol. Sci.* 2006, 102, 387–395. [CrossRef]

255. Rašković, A.; Kolarović, J.; Vukmirović, S.; Mikov, M. The Protective Effects of Silymarin against Doxorubicin-Induced Cardiotoxicity and Hepatotoxicity in Rats. *Molecules* 2011, 16, 8601–8613. [CrossRef] [PubMed]

256. Esser-Nobis, K.; Romero-Brey, I.; Ganten, T.M.; Gouttenoire, J.; Harak, C.; Klein, R.; Schemmer, P.; Binder, M.; Schnitzler, P.; et al. Analysis of Hepatitis C Virus Resistance to Silibinin In Vitro and In Vivo Points to a Novel Mechanism Involving Nonstructural Protein 4B. *Hepatology* 2013, 57, 953–963. [CrossRef] [PubMed]

257. Sardanelli, A.M.; Isgrò, G.; Palase, L.L. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome. *Molecules* 2021, 26, 1409. [CrossRef] [PubMed]

258. Payer, B.A.; Reiberger, T.; Rutter, K.; Staetttermayer, A.F.; Peck-Radosavljevic, M.; Ferenci, P. Successful HCV Eradication and Inhibition of HIV Replication by Intravenous Silibinin in an HIV-HCV Coinfected Patient. *J. Clin. Virol.* 2010, 49, 131–132. [CrossRef] [PubMed]

259. Braun, D.; Rauch, A.; Durisch, N.; Eberhard, N.; Anagnostopoulos, A.; Ledergerber, B.; Metzner, K.; Böni, J.; Weber, R.; Fehr, J. Efficacy of Lead-in Silibinin and Subsequent Triple Therapy in Difficult-to-Treat HIV/Hepatitis C Virus-Coinfected Patients. *HIV Med.* 2014, 15, 625–630. [CrossRef] [PubMed]

260. Braun, D.L.; Rauch, A.; Aoufi, M.; Durisch, N.; Eberhard, N.; Anagnostopoulos, A.; Ledergerber, B.; Möllhäuser, B.; Metzner, K.; Decosterd, L.; et al. A Lead-in with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-to-Treat HIV/Hepatitis C Virus-Coinfected Patients. *PLoS ONE* 2015, 10, e0133028. [CrossRef]

261. Bosch-Barrera, J.; Martin-Castillo, B.; Buxó, M.; Brunet, J.; Encinar, J.A.; Menendez, J.A. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. *J. Clin. Med.* 2020, 9, 1770. [CrossRef]

262. Gorla, U.S.; Rao, K.; Kula’daivelu, U.S.; Alavala, R.R.; Panda, S.P. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An In-Silico Evaluation. *Comb. Chem. High Throughput Screen.* 2020, 24, 879–890. [CrossRef]

263. Boer, M.; Duchnik, E.; Maleszka, R.; Marchlewicz, M. Structural and Biophysical Characteristics of Human Skin in Maintaining Proper Epidermal Barrier Function. *Postep. Dermatol. Alergol.* 2016, 33, 1–5. [CrossRef]

264. Benson, H.A.E.; Grice, J.E.; Mohammed, Y.; Namjoshi, S.; Roberts, M.S. Topical and Transdermal Drug Delivery: From Simple Potions to Smart Technologies. *Curr. Drug Deliv.* 2019, 16, 444–460. [CrossRef]

265. Svobodová, A.; Vostálová, J. Solar Radiation Induced Skin Damage: Review of Protective and Preventive Options. *Int. J. Radiat. Biol.* 2010, 86, 999–1030. [CrossRef] [PubMed]

266. Guillermo-Lagae, R.; Deep, G.; Ting, H.; Agarwal, C.; Agarwal, R. Silibinin Enhances the Repair of Ultraviolet B-Induced DNA Damage by Activating P53-Dependent Nucleotide Excision Repair Mechanism in Human Dermal Fibroblasts. *Oncotarget* 2015, 6, 39594–39606. [CrossRef] [PubMed]

267. Katiyar, S.K.; Mantena, S.K.; Meeran, S.M. Silimarin Protects Epidermal Keratinocytes from Ultraviolet Radiation-Induced Apoptosis and DNA Damage by Nucleotide Excision Repair Mechanism. *PLoS ONE* 2011, 6, e21410. [CrossRef] [PubMed]

268. Roy, S.; Deep, G.; Agarwal, C.; Agarwal, R. Silibinin Prevents Ultraviolet B Radiation-Induced Epidermal Damages in JB6 Cells and Mouse Skin in a P53-GADD45α-Dependent Manner. *Carcinogenesis* 2012, 33, 629–636. [CrossRef] [PubMed]

269. Rigby, C.M.; Roy, S.; Deep, G.; Guillermo-Lagae, R.; Jain, A.K.; Dhar, D.; Orlicky, D.J.; Agarwal, C.; Agarwal, R. Role of P53 in Silibinin-Mediated Inhibition of Ultraviolet B Radiation-Induced DNA Damage, Inflammation and Skin Carcinogenesis. *Carcinogenesis* 2017, 38, 40–50. [CrossRef] [PubMed]

270. Carrier, F.; Georgel, P.T.; Pourquier, P.; Blake, M.; Kontrny, H.U.; Antinone, M.J.; Gariboldi, M.; Myers, T.G.; Weinsein, J.N.; Pommier, Y.; et al. Gadd45a, a P53-Responsive Stress Protein, Modifies DNA Accessibility on Damaged Chromatin. *Mol. Cell. Biol.* 1999, 19, 1673–1685. [CrossRef]

271. Yang, X.; Zhu, L.; Zhao, W.; He, C.; Li, S.; Xu, C. GADD45α Regulates Cell Proliferation and DNA Repair of BRL-3A Cells That Treated by FZD/UVC via P38, JNK, CDC2/CCNB1, AKT and MTOR Pathways. *bioRxiv* 2017, 148759. [CrossRef]

272. Gu, M.; Dhanalakshmi, S.; Mohan, S.; Singh, R.P.; Agarwal, R. Silibinin Inhibits Ultraviolet B Radiation-Induced Mitogenic and Survival Signaling, and Associated Biological Responses in SKH-1 Mouse Skin. *Carcinogenesis* 2005, 26, 1404–1413. [CrossRef]

273. Rajnochová Svobodová, A.; Gabrielová, E.; Ulrichová, J.; Zálešík, B.; Biedermann, D.; Vostálová, J. A Pilot Study of the UVA-Photoprotective Potential of Dehydroisolybin, Isosilybin, Silychristin, and Silidyanin on Human Dermal Fibroblasts. *Arch. Dermatol. Res.* 2019, 311, 477–490. [CrossRef] [PubMed]

274. Rajnochová Svobodová, A.; Gabrielová, E.; Michaelides, L.; Kosina, P.; Ryšavá, A.; Ulrichová, J.; Zálešík, B.; Vostálová, J. UVA-Photoprotective Potential of Silymarin and Silybin. *Arch. Dermatol. Res.* 2018, 310, 413–424. [CrossRef]
275. Katiyar, S.K.; Meleth, S.; Sharma, S.D. Silymarin, a Flavonoid from Milk Thistle (Silybum marianum L.), Inhibits UV-Induced Oxidative Stress through Targeting Infiltrating CD11b+ Cells in Mouse Skin. Photochem. Photobiol. 2008, 84, 266–271. [CrossRef] [PubMed]

276. Svobodová, A.; Zdaňílová, A.; Walterová, D.; Vostálová, J. Flavonolignans from Silybum marianum Moderate UVA-Induced Oxidative Damage to HaCaT Keratinocytes. J. Dermatol. Sci. 2007, 48, 213–224. [CrossRef]

277. Hajiaghamohammadi, A.A.; Ziaee, A.; Oveisi, S.; Masroor, H. Effects of Metformin, Pioglitazone, and Silymarin Treatment on Human Keratinocytes by Silymarin. J. Dermatol. Sci. 2007, 46, 21–30. [CrossRef]

278. Li, L.H.; Wu, L.; Tashiro, S.; Onodera, S.; Uchiumi, F.; Ikejima, T. Activation of the SIRT1 Pathway and Modulation of the Cell Cycle Were Involved in Silymarin’s Protection against UV-Induced A375-S2 Cell Apoptosis. J. Asian Nat. Prod. Res. 2007, 9, 245–252. [CrossRef]

279. Juraňiová, J.; Aury-Landas, J.; Boumediene, K.; Bauge, C.; Biedermann, D.; Ulrichová, J.; Franková, J. Modulation of Skin Inflammatory Response by Active Components of Silymarin. Molecules 2019, 24, 123. [CrossRef]

280. Li, L.H.; Wu, L.J.; Tashiro, S.I.; Onodera, S.; Uchiumi, F.; Ikejima, T. Silibinin Prevents UV-Induced HaCaT Cell Apoptosis Partly through Inhibition of Caspase-8 Pathway. Biol. Pharm. Bull. 2006, 29, 1096–1101. [CrossRef]

281. Narayanapillai, S.; Agarwal, C.; Tilley, C.; Agarwal, R. Silibinin Is a Potent Sensitiser of UVA Radiation-Induced Oxidative Stress and Apoptosis in Human Keratinocyte HaCaT Cells. In Proceedings of the Photochemistry and Photobiology; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2012; Volume 98, pp. 1135–1140.

282. Altaei, T. The Treatment of Melasma by Silymarin Cream. BMC Dermatol. 2012, 12, 18. [CrossRef]

283. Cheon, H.I.; Bae, S.; Ahn, K.J. Flavonoid Silibinin Increases Hair-Inductive Property via Akt and Wnt/β-Catenin Signaling Activation in 3-Dimensional-Spheroid Cultured Human Dermal Papilla Cells. J. Microbiol. Biotechnol. 2019, 29, 321–329. [CrossRef]

284. Sharifi, R.; Pasalar, P.; Kamalinejad, M.; Dehpour, A.R.; Tavangar, S.M.; Paknejad, M.; Mehrabani Natanzi, M.; Nourbakhsh, M.; Ahmadi Ashtiani, H.R.; Akbari, M.; et al. The Effect of Silymarin (Silybum marianum) on Human Skin Fibroblasts in an In Vitro Wound Healing Model. Pharm. Biol. 2015, 53, 298–303. [CrossRef]

285. Tabari, S.A.; Carpi, S.; Polini, B.; Nieri, P.; Esfahani, M.A.; Ghorbani, H.; Ranaei, M.; Kazemi, S. Topical Application of Silymarin Enhances Cutaneous Wound Healing in Rats. South African J. Bot. 2019, 124, 494–498. [CrossRef]

286. Oryan, A.; Tabatabaei Naeini, A.; Moshiri, A.; Mohammadalipour, A.; Tabandeh, M.R. Modulation of Cutaneous Wound Healing by Silymarin in Rats. J. Wound Care 2012, 21, 457–464. [CrossRef]

287. Vostálová, J.; Tinková, E.; Biedermann, D.; Kosina, P.; Ulrichová, J.; Svobodová, A.R. Skin Protective Activity of Silymarin and Its Flavonolignans. Molecules 2019, 24, 1022. [CrossRef]

288. Ebrahimpour Koujan, S.; Gargari, B.P.; Mobasser, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Effects of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplement on Antioxidant Status and Hs-CRP in Patients with Type 2 Diabetes Mellitus: A Randomized, Triple-Blind, Placebo-Controlled Clinical Trial. Phytochemistry 2015, 292, 290–296. [CrossRef]

289. Ebrahimpour-koujan, S.; Gargari, B.P.; Mobasser, M.; Valizadeh, H.; Asghari-Jafarabadi, M. Lower Glycemic Clinical Advantage in Using a Fixed Combination of Berberis Aristata (L.) Gaertn. (Silymarin) Extract Supplementation on Antioxidant Status and Hs-CRP in Patients with Type 2 Diabetes Mellitus Patients Who Received Novel Dose of Silybum marianum (L.) Gaertn. (Silymarin) Extract Supplement: A Triple-Blinded Randomized Controlled Clinical Trial. Phytochemistry 2018, 44, 39–44. [CrossRef]

290. Derosa, G.; D’Angelo, A.; Maffioli, P. The Role of a Fixed Berberis Aristata/Silybum marianum Combination in the Treatment of Type 1 Diabetes Mellitus. Clin. Nutr. 2016, 35, 1091–1095. [CrossRef]

291. Di Pierro, F.; Putignano, P.; Villanova, N.; Montesi, L.; Moscatiello, S.; Marchesini, G. Preliminary Study about the Possible Glycemic Clinical Advantage in Using a Fixed Combination of Berberis Aristata and Silybum marianum Standardized Extracts versus Only Berberis Aristata in Patients with Type 2 Diabetes. Clin. Pharmacol. Adv. Appl. 2013, 5, 167–174. [CrossRef] [PubMed]

292. Hahn, H.J.; Jung, H.J.; Schrammek-Drusios, M.C.; Lee, S.N.; Kim, J.H.; Kwon, S.B.; An, I.S.; An, S.; Ahn, K.J. Instrumental Evaluation of Anti-Aging Effects of Cosmetic Formulations Containing Palmitoyl Peptides, Silymarin, Vitamin E and Other Functional Ingredients on Aged Human Skin. Exp. Ther. Med. 2016, 12, 1171–1176. [CrossRef] [PubMed]

293. Alanbari, H.; Sahib, A.; Raghib, A. Effects of Silymarin, N-Acetylcysteine and Selenium in the Treatment of Papulopustular Acne. Oxid. Antioxid. Med. Sci. 2012, 1, 201–207. [CrossRef]

294. Curcio, A.; Romano, C.; Cuozzo, S.; Di Nicola, A.; Grassi, O.; Schiarioli, D.; Nocera, G.F.; Pironti, M. Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients. Medicina 2020, 56, 544. [CrossRef] [PubMed]

295. Hajaraghomammedi, A.A.; Ziaee, A.; Oveis, S.; Masroor, H. Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study. Hepat. Mon. 2012, 12, 6099. [CrossRef]

296. Aller, R.; Izaola, O.; Gómez, S.; Tafur, C.; González, C.; Berroa, E.; Mora, N.; González, J.M.; De Luis, D.A. Effect of Silymarin plus Vitamin E in Patients with Non-Alcoholic Fatty Liver Disease. A Randomized Clinical Pilot Study. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 3118–3124.

297. Abenavoli, L.; Greco, M.; Nazionale, I.; Peta, V.; Milic, N.; Accattato, F.; Foti, D.; Gulletta, E.; Luzzu, F. Effects of Mediterranean Diet Supplemented with Silybin-Vitamin E-Phospholipid Complex in Overweight Patients with Non-Alcoholic Fatty Liver Disease. Expert Rev. Gastroenterol. Hepatol. 2015, 9, 519–527. [CrossRef]

298. Federico, A.; Dallio, M.; Gravina, A.G.; Diano, N.; Errico, S.; Masarone, M.; Romeo, M.; Tuccillo, C.; Stiuso, P.; Morisco, F.; et al. The Bisphenol a Induced Oxidative Stress in Non-Alcoholic Fatty Liver Disease Male Patients: A Clinical Strategy to Antagonize the Progression of the Disease. Int. J. Environ. Res. Public Health 2020, 17, 3369. [CrossRef] [PubMed]
299. Solhi, H.; Ghahremani, R.; Kazemifar, A.M.; Yazdi, Z.H. Silymarin in Treatment of Non-Alcoholic Steatohepatitis: A Randomized Clinical Trial. *Casp. J. Intern. Med.* 2014, 5, 9–12.

300. Wah Kheong, C.; Nik Mustapha, N.R.; Mahadeva, S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. *Clin. Gastroenterol. Hepatol.* 2017, 15, 1940–1949.e8. [CrossRef] [PubMed]

301. Navarro, V.J.; Bell, S.H.; D’Amato, M.; Adfhal, N.; Brun, E.M.; Fried, M.W.; Rajender Reddy, K.; Wahed, A.S.; Harrison, S. Silymarin in Non-Cirrhotics with Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo Controlled Trial. *PLoS ONE* 2019, 14, e0221683. [CrossRef]

302. Abbasirad, F.; Shaygannejad, V.; Hosseininasab, F.; Mirmosayyeb, O.; Mahaki, B.; Moayedi, B.; Esmaeil, N. Significant Immunomodulatory and Hepatoprotective Impacts of Silymarin in MS Patients: A Double-Blind Placebo-Controlled Clinical Trial. *Int. Immunopharmacol.* 2021, 97, 107715. [CrossRef]

303. Luangchosiri, C.; Thakkinstian, A.; Chitphuk, S.; Stitchantrakul, W.; Petraksa, S.; Sobhonslidsuk, A. A Double-Blinded Randomized Controlled Trial of Silymarin for the Prevention of Antituberculosis Drug-Induced Liver Injury. *BMC Complement. Altern. Med.* 2015, 15, 334. [CrossRef]

304. Marjani, M.; Baghaei, P.; Dizaji, M.K.; Bayani, P.G.; Fahimi, F.; Tabarsi, P.; Velayati, A.A. Evaluation of Hepatoprotective Effect of Silymarin among under Treatment Tuberculosis Patients: A Randomized Clinical Trial. *Iran. J. Pharm. Res.* 2016, 15, 247–252. [CrossRef]

305. Heo, E.; Kim, D.K.; Oh, S.H.; Lee, J.K.; Park, J.H.; Chung, H.S. Effect of Prophylactic Use of Silymarin on Anti-Tuberculosis Drugs Induced Hepatotoxicity. *Tuberc. Respir. Dis.* 2017, 80, 265–269. [CrossRef]

306. Moayedi, B.; Gharagozloo, M.; Esmaeil, N.; Maracy, M.R.; Hoorfar, H.; Jalaeikar, M. A Randomized Double-Blind, Placebo-Controlled Study of Therapeutic Effects of Silymarin in $\beta$-Thalassemia Major Patients Receiving Desferrioxamine. *Eur. J. Haematol.* 2013, 90, 202–209. [CrossRef] [PubMed]

307. Gharagozloo, M.; Karimi, M.; Amirghofran, Z. Immunomodulatory Effects of Silymarin in Patients with $\beta$-Thalassemia Major. *Int. Immunopharmacol.* 2013, 16, 243–247. [CrossRef] [PubMed]

308. Hagag, A.A.; Elfaragy, M.S.; Gazar, R.A.; El-Lateef, A.E.A. Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia. *Mediterr. J. Hematol. Infect. Dis.* 2013, 5, 1–7. [CrossRef]

309. Balouchi, S.; Gharagozloo, M.; Esmaeil, N.; Mirmohghtadaei, M.; Moayedi, B. Serum Levels of TGF$\beta$, IL-10, IL-17, and IL-23 Cytokines in $\beta$-Thalassemia Major Patients: The Impact of Silymarin Therapy. *Immunopharmacol. Immunotoxicol.* 2014, 36, 271–274. [CrossRef]

310. Hagag, A.; Elfaragy, M.; Elrifaey, S.; Abd El-Lateef, A. Therapeutic Value of Combined Therapy with Deferiprone and Silymarin as Iron Chelators in Egyptian Children with Beta Thalassemia Major. *Infect. Disord.-Drug Targets* 2015, 15, 189–195. [CrossRef] [PubMed]